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Abstract 
Brent A. Penque 
 
MECHANISMS OF HEXOSAMINE-INDUCED CHOLESTEROL 
ACCUMULATION AND THERAPEUTIC ACTIONS OF CHROMIUM 
 
Excess caloric intake and/or obesity currently remain the largest 
predisposing risk factors for the development of type 2 diabetes. Discerning the 
cellular and molecular mechanisms responsible and amendable to therapy 
represents a growing challenge in medicine. At a cellular level, increased activity 
of the hexosamine biosynthesis pathway (HBP), a sensor of excess energy 
status, has been suggested to promote the exacerbation of insulin resistance 
through increasing adipose tissue and skeletal muscle membrane cholesterol 
content. This in turn compromises cortical filamentous actin structure necessary 
for proper incorporation of the insulin-sensitive glucose transporter GLUT4 into 
the plasma membrane. The current studies attempted to elucidate the 
mechanism by which hexosamines provoke membrane cholesterol toxicity and 
insulin resistance. In 3T3-L1 adipocytes cultured with pathophysiologic 
hyperinsulinemia to induce insulin resistance, increased HBP flux was observed. 
This occurred concomitant with gains in the mRNA and protein levels of HMG-
CoA reductase (HMGR), the rate limiting enzyme in cholesterol synthesis. 
Mechanistically, immunoprecipitation demonstrated increased HBP-induced N-
acetylglucosamine (O-GlcNAc) modification of specificity protein 1 (Sp1), a 
regulator of HMGR synthesis. This was associated with increased affinity toward 
vii 
 
and activity of Hmgcr, the gene encoding HMGR. Global HBP inhibition or Sp1 
binding to DNA prevented membrane cholesterol accrual, filamentous actin loss, 
and glucose transport dysfunction. Furthermore, hyperinsulinemia and HBP 
activation impaired cholesterol efflux in adipocytes, exacerbating cholesterol 
toxicity and potentially contributing to cardiovascular disease. In this regard, 
chromium picolinate (CrPic), known to have beneficial effects on glucose and 
lipoprotein metabolism, improved cholesterol efflux and restored membrane 
cholesterol content. To test the role of membrane cholesterol accumulation in 
vivo, studies were conducted on C57Bl/6J mice fed a low or high fat diet. High fat 
feeding promoted increased HBP activity, membrane cholesterol accumulation, 
and insulin resistance. Supplementation of mice with CrPic in their drinking water 
(8µg/kg/day) countered these derangements and improved insulin sensitivity. 
Together, these data provide mechanistic insight for the role of membrane 
cholesterol stress in the development of insulin resistance, as well as 
cardiovascular disease, and highlight a novel therapeutic action of chromium 
entailing inhibition of the HBP pathway.   
 
                  
               Jeffrey S. Elmendorf, Ph.D., Chair 
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Chapter I. Introduction 
 In the health care field, a growing concern has emerged over the increased 
incidence of chronic disease in patient populations. Complex diseases involving 
multisystem pathologies are becoming increasingly prevalent. Despite enormous 
medical progress, type 2 diabetes (T2D), cardiovascular disease (CVD) and 
cancer remain worldwide health problems. In this regard, excessive caloric intake 
and sedentary lifestyles in the developed world have greatly contributed to the 
increased prevalence of T2D. Compounding this “energy balance” model is the 
fact that rather than a restabilization or plateauing of weight at a higher level, 
weight continues to escalate, suggesting a major contributing role of dietary 
composition on metabolic derangements and T2D progression (1). In addition, 
T2D is known to be an independent risk factor for the development of CVD (2, 3). 
According to the United States Centers for Disease Control and Prevention 2011 
National Diabetes Fact Sheet (4), an estimated 25.8 and 79 million Americans 
have diabetes and pre-diabetes, respectively. Worldwide projections of the 
incidence of diabetes continue to escalate each year, with recent predictions that 
almost a half billion individuals will have T2D by 2030 (5). Augmenting this 
problem are the healthcare and economic burdens of this disease. In 2007, the 
total direct and indirect costs associated with T2D were $174 billion. Diabetes 
affects multiple physiological systems and is the leading cause of blindness, 
heart failure, stroke, kidney failure, non-traumatic lower limb amputations, and 
gum disease. The burden this disease continues to have on families necessitates 
the need for better prevention and treatment. Clinical measures used to delay the 
onset of this disease, however, are often limited. Diet and exercise are proven, 
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effective methods to attenuate disease progression, but have been met with 
limited patient compliance. Efficacious medications have been developed to 
alleviate insulin resistance, yet reports of adverse effects (e.g., hypoglycemia, 
weight gain, abnormal liver function, gastrointestinal, lactic acidosis, etc.) compel 
the need for future research into novel therapies.  
 Insulin resistance represents a hallmark feature that presents early in the 
development of T2D and is a major therapeutic target. Insulin resistance clinically 
is defined as a reduced ability of insulin to lower plasma glucose levels. In 
skeletal muscle and adipose tissue, this correlates to a loss in insulin-stimulated 
glucose uptake. In the liver, this results in attenuation of insulin’s inhibitory effects 
on hepatic glucose production and output. Beyond regulating glucose transport, 
insulin resistance also promotes release of fatty acids (FAs) stored in fat. In a 
healthy individual, insulin inhibits lipolysis in adipose tissue through the 
phosphodiesterase 3B-mediated degradation of cellular cyclic AMP (6). This 
event suppresses protein kinase A-mediated phosphorylation and activation of 
hormone-sensitive lipase and perilipin A. Inhibition of these proteins prevents the 
activation of lipases responsible for the breakdown and release of FAs. A primary 
consequence of insulin resistance is that adipose tissue becomes refractory to 
the inhibitory effect of insulin, resulting in excess circulating FAs. In addition, 
insulin resistance and subsequent glucose intolerance itself are widely believed 
to promote compensatory hyperinsulinemia. This hyperinsulinemia is initially 
thought to help maintain normoglycemia. Yet hyperinsulinemia, excess 
circulating FAs, and hyperglycemia have been shown to impinge upon insulin 
sensitivity in vitro as well as in animal and man (7-15). This results in a vicious 
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cycle promoting further hyperinsulinemia which, in turn, exacerbates insulin 
resistance. Ultimately, this glucose and lipid toxicity is known to promote the 
progressive impairment in the ability of the β cells of the pancreas to produce and 
secrete insulin, leading to the diagnosis of frank T2D.  
 As insulin resistance represents an early abnormality in the progression of 
diabetes, research efforts have sought to understand the mechanisms fueling its 
development. In adipocytes and skeletal muscle, pathophysiologic 
hyperinsulinemia has been shown to promote insulin resistance in absence of 
insulin signaling defects (8, 12, 16-18). An emerging appreciation is that 
downstream defects that transpire at or near the plasma membrane (PM) may 
contribute to dysregulation of glucose transport into these tissues. In this context, 
our lab has demonstrated that increases in PM cholesterol content, induced by 
hyperinsulinemia, perturb cortical filamentous actin (F-actin) structure that is 
essential for insulin-stimulated glucose transport. Our studies further suggest 
increased hexosamine biosynthesis pathway (HBP) activity as a basis for 
hyperinsulinemia-induced increases in PM cholesterol content (7, 11). 
Interestingly, we have also found increased HBP activity increases endosomal 
membrane cholesterol levels in adipocytes, impairing the proper trafficking of the 
ATP-binding cassette transporter (ABCA1), necessary for cholesterol efflux (19).  
 Therapeutically, the trivalent micronutrient, chromium (Cr3+) has been known 
since the 1950’s to benefit glucose and lipid metabolism (20), yet the mechanism 
of action remains incompletely understood. Recent study has shown, however, 
that Cr3+ can lower PM and endosomal membrane cholesterol levels, improving 
insulin sensitivity and cholesterol efflux processes (19, 21, 22). In addition, a 
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systematic review has also demonstrated that Cr3+ effectively improved 
hyperglycemia in patients with T2D (23).  
 In the following subsections of this chapter, I will highlight the fundamental 
actions of insulin in maintaining glucose homeostasis. I will subsequently discuss 
how this process goes awry in the context of the diabetic milieu, with emphasis 
on the role of the HBP in promotion of this phenotype. I will then detail 
mechanisms by which increased HBP activity may impair lipoprotein metabolism, 
and finally discuss the beneficial actions of Cr3+ supplementation on improving 
glucose and lipid homeostasis. In Chapter II, I will present my thesis work 
published in Molecular Endocrinology (24) and Arteriosclerosis, Thrombosis and 
Vascular Biology (19) demonstrating a novel mechanism by which HBP-induced 
transcriptional activation of cholesterol synthesis impairs glucose and cholesterol 
transport. I will further present study in preparation for submission to Diabetes 
demonstrating beneficial actions of Cr3+ entail countering aberrant HBP activity 
and cholesterol accumulation. In Chapter III, I will place my thesis work within the 
context of the current body of knowledge in the field of diabetes and 
cardiovascular health. I will also identify future questions and studies which could 
serve to enhance the understanding of these mechanisms fueling disease 
progression. 
 
I.A. Insulin-Mediated Glucose Regulation 
 The hormone insulin is essential for several processes within the body, from 
regulation of protein synthesis to the modulation of the activity of numerous 
enzymes. Importantly, insulin is a primary hormone responsible for the regulation 
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of glucose homeostasis in the post-prandial state. Upon ingestion of a meal, 
glucose enters the bloodstream and is sensed by the endocrine pancreas, 
specifically β cells in the islets of Langerhans. Glucose then stimulates the 
secretion of insulin from the pancreas into the circulation. Importantly, insulin is a 
relatively fast-acting hormone that needs to respond to rapidly changing levels of 
glucose in the bloodstream. As such, the half-life of insulin in the plasma is 
actually quite short, ranging from 4-6 minutes (25, 26). In fact, at first pass to the 
liver, approximately 50% of insulin is cleared from the body through receptor-
mediated endocytosis. Insulin that has not been cleared exerts its primary effects 
on glucose regulation in hepatic and adipose tissue, as well as skeletal and 
cardiac muscle. In the liver, insulin decreases gluconeogenesis and 
glycogenolysis while stimulating glucose storage as glycogen. In striated muscles 
and adipose tissue, insulin stimulates glucose transport, allowing for glucose flux 
through oxidative pathways to produce the energy needs of the cell. Remaining 
systemic insulin is ultimately removed by endocytic processes in insulin-sensitive 
tissues or by reabsorption of insulin in the proximal tubular cells of the kidney. In 
addition, insulin also negatively impinges upon its own secretion in the β cell. 
Through these processes, the body is able to constantly respond and precisely 
control whole-body glucose homeostasis. Under healthy conditions, plasma 
glucose concentrations will not fall below 70 mg/dL or increase beyond 100 
mg/dL in the fasted state. Further, two hours following an oral glucose tolerance 
test, plasma glucose should not rise above 140 mg/dL. The focus of this thesis is 
to understand the molecular mechanisms of insulin-mediated glucose transport 
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into adipose tissue and skeletal muscle and how this process becomes 
dysregulated into the context of insulin resistance.  
 
I.A.1. Integrative Actions of Insulin  
At a cellular level, insulin-stimulated glucose transport into adipose tissue 
and striated muscle is mediated through its ability to stimulate the subcellular 
trafficking of the insulin-sensitive glucose transporter GLUT4 from intracellular 
pools to the PM (27-29). While at least 14 other glucose transporter isoforms 
exist in various tissues (30), GLUT4 is localized to insulin-sensitive striated 
muscle as well as brown and white adipose tissue. The binding of insulin to its 
surface receptor on the PM triggers a large increase in the exocytosis of GLUT4 
to the PM. In adipocytes and L6 muscle cells, insulin has also been shown to 
reduce the rate of GLUT4 endocytosis (31-34). This rate-limiting step in glucose 
uptake and utilization results in the population of the PM with GLUT4 to facilitate 
glucose entry into these tissues. In fact, approximately 90% of post-prandial 
glucose disposal is mediated in these two tissues (35).  
Extending beyond striated muscle and adipose tissue, the liver plays a major 
role in the maintenance of glucose homeostasis. Insulin exerts its effects on the 
liver through post-translational modification and transcriptional repression of 
genes involved in glucose production (36). Upon binding to its cell surface 
receptor in hepatocytes, insulin stimulates a phosphorylation cascade that results 
in the phosphorylation of Akt (protein kinase B, PKB) which in turn 
phosphorylates the forkhead box protein (FOXO1). This phosphorylation event 
has been shown to restrict the access of FOXO1 to the nucleus, thereby 
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suppressing its transcription of glucose-6-phosphatase (G6Pase) as well as 
phosphoenolpyruvate carboxykinase (PEPCK), two enzymes involved in 
gluconeogenesis (37). By modulation of FOXO1 activity, insulin is also able to 
suppress peroxisome proliferator-activated receptor-γ co-activator-1α (PGC-1α), 
a transcriptional co-activator known to activate the entire gluconeogenic pathway 
(38). In effect, this modification of FOXO1 prevents its association with PGC-1α 
to activate gluconeogenesis. Gluconeogenesis is also indirectly suppressed in 
the liver through a decrease in the secretion of glucagon by the α cells of the 
endocrine pancreas.  
Finally, recent studies have provided evidence that the central nervous 
system (CNS) also plays a significant role in glucose homeostasis (39-43). CNS 
regulation of food intake is a complex process involving a variety of short-term 
and long-term signals. Yet insulin action on the CNS is now thought to mediate 
glucose homeostasis through inhibition of hepatic glucose output. For example, 
insulin is known to activate ATP-sensitive potassium channels in neurons found 
in the arcuate nuclei of the hypothalamus (44, 45). Activation of these channels 
through central administration of diazoxide promotes a reduction in blood glucose 
levels in rats (46). While the precise mechanisms by which CNS insulin action 
may inhibit hepatic glucose production are unknown, it is suggested that it 
requires interleukin 6-mediated phosphorylation of hepatic signal transducer and 
activator of transcription 3 (STAT3) (41, 42, 47). Phosphorylation of STAT3 
reduces PEPCK and G6Pase expression and protein levels, thereby inhibiting 
gluconeogenesis. Despite this, other study suggests that insulin’s direct inhibition 
on hepatic glucose output is dominant, while insulin’s effects on the CNS to 
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inhibit this process are redundant (48). These data suggest that dysregulated 
gluconeogenesis in insulin-resistant states may also be due to a loss of insulin 
action in the CNS. Regardless of the exact role of insulin action in the CNS, 
insulin resistance in the brain is known to contribute to cognitive impairment and 
Alzheimer’s disease, recently characterized as a potential “type 3 diabetes” (49).  
 
I.A.2. Insulin Signaling and GLUT4 Recruitment 
The precise networks by which insulin regulates glucose transport via 
recruitment of GLUT4 to the PM in fat and muscle cells are complex and still 
imperfectly understood. Upon binding of insulin to the PM localized insulin 
receptor, the intrinsic tyrosine kinase activity of the receptor is stimulated (Fig. 1). 
This event results in the autophosphorylation of tyrosine residues on the β-
subunit (50, 51). Phosphorylation of the insulin receptor stimulates a 
phosphorylation cascade involving the insulin receptor substrate (IRS) docking 
proteins. Although there are 6 different isoforms of IRS, IRS1 and IRS2 have 
been established through knockdown studies in cell culture and mice to be the 
primary mediators of glucose transport (52-54). 
The next step leading to translocation of glucose storage vesicles (GSVs) 
containing GLUT4 to the PM requires the activation of phosphatidylinosital 3-
kinase (PI3K) by IRS. PI3K stimulates the conversion of phosphatidylinositol 4,5-
bisphophate (PIP2) to phosphatidylinositol (3,4,5)-triphosphate (PIP3). PIP3 then 
facilitates the recruitment Akt and phosphoinositide-dependent kinase 1 (PDK1) 
to the PM, where Akt then becomes phosphorylated and active. Akt subsequently 
phosphorylates and inhibits the GTPase activating domain (GAP) of Akt
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Figure 1. Schematic of the steps involved in GLUT4 recruitment, tethering 
and docking, and fusion. 
Insulin binding to its receptor triggers a phosphorylation cascade resulting in the 
activation of tissue specific Rab proteins. These Rab proteins are in turn 
responsible for the recruitment of GLUT4 containing vesicles along microtubule 
and cytoskeletal tracks to the PM. A host of signaling, motor, cytoskeletal, and 
membrane proteins and lipids play vital roles in this trafficking process (see text 
for expanded details).  
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substrate of 160-kilodaltons (AS160, TBC1D1). Currently, there are three known 
isoforms of Akt. Similar knockdown studies identified Akt2 as the predominant 
isoform responsible for glucose uptake into muscle and fat tissues, although Akt1 
is thought to play a minor role (55-57). Phosphorylation of AS160 allows for Rab-
mediated trafficking of GSVs to the PM. Of note, another Rab-GAP, TCB1D1, 
has been implicated in insulin-mediated regulation of GLUT4 exocytosis and is 
particularly abundant in skeletal muscle (58, 59). The tissue-specific isoforms of 
Rab proteins targeted by AS160 and TCB1D1 are currently under study. Rab8A 
and Rab14 are postulated to be the predominant isoforms in skeletal muscle, 
whereas Rab10 is the important isoform in adipose tissue (60). Additionally, 
Rab4, 5, and 11 have also been shown to associate with the GSVs (61, 62).  
The subsequent steps by which Rab proteins mediate the translocation of 
GSVs are under investigation. Two models have been proposed to explain how 
insulin regulates these distal effects. The most popular model is the retention 
model (63). In this model, GSVs are anchored to the interior of the cell, 
preventing movement on cytoskeletal tracks under basal conditions. In the 
absence of insulin stimulation, Rab proteins are found in inactive states and thus 
hinder the vesicle attachment to the microtubules. Support for this hypothesis 
comes from research that has shown Rab4 binding to the microtubule motor 
protein kinesin family member 3 (KIF3) is dependent on insulin (64, 65). Another 
model, the repulsion model, suggests that GSVs can constantly access the PM, 
despite the absence of insulin (63). Rather, GSVs that arrive at the PM are 
repelled, and the action of insulin is to stimulate fusion and prevent this repulsion. 
Evidence for this model comes from recent advances in the field of microscopy 
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that allow for the resolution of GLUT4 within 150 nm of the PM. Total internal 
reflection fluorescence microscopy supports this contention as numerous studies 
have shown these structures near the membrane in the absence of insulin (66-
68). A complete understanding of the precise mechanisms leading to GLUT4 
docking and fusion at the PM will require higher resolution techniques to examine 
these processes in live cells.  
In addition to the canonical insulin signaling pathway, phosphoinositides 
derived from PI3K are known to activate atypical protein kinase C (aPKC, 
PKCλ/ζ). Knockout of PKCλ specifically in mouse muscle provokes systemic 
insulin resistance and glucose intolerance (69), suggesting an important role in 
mediating insulin-stimulated glucose uptake. It is believed that aPKC acts at the 
level of promoting GLUT4 translocation, and studies suggest that PKCλ and 
PKCζ may orchestrate these processes through Rac1-mediated reorganization of 
the cytoskeleton (70).  
 
I.A.3. GLUT4 Trafficking and PM Fusion 
Conceptually, it is evident that GLUT4 trafficking to the PM requires the 
coordinated effort of multiple carriers along its track. In the basal state, GLUT4 
can be found in both GSVs as well as in larger structures formed from the trans-
Golgi network (TGN) and endosomes. In adipocytes, movement of GLUT4 along 
microtubule tracks is thought to be mediated primarily by kinesin superfamily 
proteins KIF5B and KIF3 (64, 65). As mentioned previously, in rat adipose cells, 
cryosectioning and immunoelectron microscopy showed that GLUT4 was located 
just beneath the PM (71). In line with the repulsion model, this suggests that the 
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major function of these microtubule networks is to continuously supply GLUT4 to 
the PM.  
Having reached close proximity to the PM via the microtubule network, 
several complexes have been suggested to serve independently or in 
collaboration to tether the vesicle to the PM for fusion. It is well documented that 
F-actin just below the surface of the membrane plays a role in this process (72-
74). Functionally, insulin causes a rapid remodeling of actin into a cortical mesh 
required for GLUT4 translocation. Study has identified myosin motors MYO5 and 
MYO1C on GSVs and suggested these may serve to anchor them to the actin 
meshwork (75-77). Essential to the rearrangement of the actin to facilitate this 
anchoring are several insulin-regulated proteins (e.g., TC10 (78, 79)), actin-
related proteins 2/3 (Arp2/3), and Cofilin, Myo1c, Rac1, and focal adhesion 
kinase (80). Additionally, phosphoinositides are also known to regulate the actin 
cytoskeleton necessary for GLUT4 translocation (72). Multiple studies have 
shown that stimulating the hydrolysis or sequestering PIP2 results in a depletion 
of cortical F-actin (81-85). Importantly, the precise regulation of these processes 
leading to the formation of this F-actin mesh is necessary for GLUT4 arrival at 
the PM. Disruption of the F-actin structure using the actin depolymerizing agent 
cytochalasin D, for instance, causes an inhibition in insulin-stimulated GLUT4 
redistribution (86-88).  
In addition to the actin meshwork, the formation of what is referred to as the 
exocyst, perhaps mediated by actin itself, is needed for the arrival of GLUT4 to 
the PM. This octameric protein is responsible for the spatial targeting of GSVs to 
the PM. Research has shown that the exocyst has numerous interactions with 
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phospholipids at the PM, actin, Arp2/3, aPKC, small G-proteins (Rab8, Rab10, 
Rab11), and soluble NSF attachment protein receptors (SNARE) (89-91). The 
formation of the exocyst complex upon insulin stimulation is thought to occur at 
PM caveolae regions, small invaginations (50-100 nm) in the PM rich in lipids 
and cholesterol (80). Binding of GSVs to the exocyst complex ultimately leads to 
the formation of a SNARE complex responsible for GLUT4 fusion with the PM.  
The SNARE complex consists of both target membrane SNARES 
(tSNARES), SNAP-23 and Syntaxin-4, as well as vesicle SNARE (vSNARE) 
protein VAMP2. The association of these vesicle and target membrane SNARES 
is thought to promote the final steps in the fusion process. This process has been 
described as analogous to the closing of a zipper. The formation of a complex 
between tSNARES and vSNARES is highly stable. The stability conferred by this 
binding and subsequent “zippering” is thought to overcome the energy barrier 
required, thereby serving as a catalyst to merge these two membranes (92). An 
important regulator of this process is the protein Munc18c, which itself is 
activated by the insulin receptor (93, 94). Munc18c is known to be a direct 
binding partner of Syntaxin 4 (93). One hypothesis suggests that Munc18c is 
normally inhibitory to GLUT4 exocytosis by keeping Syntaxin 4 in an inactive 
conformation. Phosphorylation of Munc18c by the insulin receptor then results in 
its dissociation from Syntaxin 4, allowing for complex formation to occur. Support 
for this comes from studies showing that adipocytes from Munc18c null mice 
have an increased sensitivity to insulin-stimulated GLUT4 translocation (95). 
Additionally, overexpression of Munc18c inhibits GLUT4 exocytosis (5, 96-98). 
Recent study has also suggested that insulin signaling through conventional PKC 
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or PKCζ may promote the dissociation between these two proteins (99, 100). 
Future studies are aimed at carefully dissecting how this phosphorylation event 
precisely directs the final mechanisms leading to PM fusion events. 
 
I.A.4. PM Lipids Regulating GLUT4 Exocytosis 
As previously mentioned, the formation of the complex machinery that 
facilitates GLUT4 translocation is thought to occur just below the PM in caveolae 
invaginations, stabilized by the caveolin proteins (101). Although the investigation 
of these structures has proven extremely difficult, double labeling studies have 
shown that F-actin appears to emanate from the neck regions of caveolae (87, 
102). In addition, disruption of the caveolae with the cholesterol solubilizing 
agent, methyl-β-cyclodextrin, was shown to disrupt the localization of this F-actin 
(87). These findings suggest that this lipid-rich region of the PM may play an 
essential role in mediating F-actin reorganization necessary for optimal tethering, 
docking, and fusion events. Further support for this comes from findings that in 
adipocytes, these lipid regions are necessary for the activation of TC10 (103, 
104). A key role of PIP2 has been proposed in this process as electron 
microscopy has shown high concentrations of this lipid at the rim of caveolae 
structures, consistent with its role in regulating the actin cytoskeleton (105). 
These findings are interesting in the context of work in our lab suggesting that 
hyperinsulinemia promotes a loss of PIP2 and F-actin structure and that 
exogenous add back of PIP2 restores F-actin structure and insulin 
responsiveness (8, 12). Of further note, hyperinsulinemia and hyperlipidemia 
have been shown to provoke increases in PM cholesterol content correlated with 
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these losses in PIP2 and F-actin in 3T3-L1 adipocytes and L6 myotubes. 
Strikingly, removal of this excess cholesterol reversed a loss in F-actin structure 
and impaired insulin responsiveness (11). Together, this data formed a basis for 
my thesis work aimed on dissecting how metabolic syndrome promotes 
cholesterol accumulation at the PM.  
Another role of lipids in regulating the final steps in fusion events comes from 
studies regarding phospholipase D (PLD) activity. PLD has been shown to be 
required for the insertion of GLUT4 into the PM (106, 107). Insulin stimulation in 
adipocytes is known to recruit PLD to the PM. While the exact mechanisms of a 
direct role of PLD in mediating fusion have yet to be elucidated, PLD is known to 
activate phosphatidylinositol 4-phosphate 5-kinase, resulting in the production of 
PIP2 necessary for exocytosis (108, 109). It is also believed that PLD may serve 
a function in lowering the energy of activation needed for membrane curving 
during the generation and expansion of fusion pores (110).  
In summary, a wide variety of machinery is responsible for signaling GLUT4 
exocytosis. The precise molecular details regarding the final steps are continuing 
to emerge. The role of my current work was to gain further insight into how these 
processes may go awry in the context of the diabetic milieu. Importantly, my 
research has focused on methods to correct against abnormalities in these 
processes to attempt to restore insulin responsiveness. Finally, alterations in 
these regulatory nodes have been shown to decrease the generation of 
atheroprotective high density lipoprotein cholesterol (HDL). Thus, attempts to 
establish new strategies to attenuate insulin resistance and alterations in 
lipoprotein metabolism are of pivotal importance.  
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I.B. Mechanisms of Insulin Resistance  
Over the past 20 years, the major driving force for research in the diabetes 
field was the attempt to determine the chief molecular derangement responsible 
for the development of insulin resistance. Since then, it is recognized that an 
increasing number of cellular, endocrine, inflammatory, and neuronal 
derangements are involved in this process (111). A major clinical challenge is 
that while many of these pathways are interdependent, therapeutic treatments 
that counter just one mechanism may fail to result in significant glycemic 
improvements in patients. In this regard, many of the same cellular 
derangements (ER, oxidative, PM stress, and mitochondrial dysfunction) occur in 
multiple tissues, creating further challenges for therapeutic intervention. Thus, a 
concerted effort to discern the precise temporal sequence for appearance of 
these effects may prove invaluable to prevent the exacerbation of insulin 
resistance to β cell failure. The goal of this section is to review the primary 
mechanisms involved in fat, glucose, and insulin-induced insulin resistance, with 
emphasis on the emerging role of the HBP in fueling many of these processes. 
This section will also highlight how insulin resistance may promote alterations in 
lipoprotein metabolism, a secondary goal of my research.  
 
I.B.1. Fat-Induced Insulin Resistance    
It has been widely recognized that plasma concentrations of FAs are 
commonly elevated in obese, insulin resistant humans and that this process is 
mainly driven by an inappropriate storage/release of FA stores in adipocytes 
(112-114). It should be noted, however, that clinical trials have shown that 
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elevations in intake of FAs can impair insulin sensitivity independent of body 
weight (115). The first model whereby FAs could disrupt glucose metabolism 
came in 1963 when Philip Randle postulated that a competition could occur 
between oxidation and utilization of FAs or glucose in insulin-sensitive tissues 
(116). This model, referred to as the Randle cycle, involves glucose oxidation’s 
generation of malonyl-CoA which can bind to and inhibit tissue-specific isoforms 
of carnitine palmitoyltransferase. This binding prevents FA transport to the 
mitochondria, thereby suppressing FA oxidation. In the years following, greater 
attention has been on the role FAs could have on suppressing glucose uptake 
rather than oxidative pathways. This led to the formation of the Shulman 
hypothesis, which suggests that FA metabolites, such as ceramides, 
diacylglyerol, and acyl-CoA, play active roles in inhibiting insulin-stimulated 
glucose transport (117). These signaling proteins can activate c-Jun N-terminal 
kinases (JNK), either through activation of PKCθ or through toll-like receptor 4 
(TLR4), leading to attenuation of insulin signaling by inhibitory Ser/Thr 
phosphorylation and/or degradation of the insulin receptor (111, 118-120).  
An additional observation with regard to FA-induced insulin resistance is that 
insulin resistance is dictated not just by the amount, but also by the specific 
composition of FAs ingested (115). For instance, studies in animal and man 
demonstrate that HF diets rich in saturated FAs impair insulin action (52, 121-
123). One particular randomized crossover study suggests that in healthy 
individuals, saturated FAs may not impair insulin sensitivity, but rather that 
overweight individuals may be more susceptible to insulin resistance due to 
saturated FAs (124). This may suggest that saturated FAs are an exacerbating 
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factor in the development of insulin resistance. Nevertheless, the saturated FA 
palmitate, most prevalent in the circulation, was found to induce insulin 
resistance through de novo synthesis of ceramides (125). These studies have 
shown that this process entails palmitate increasing mRNA encoding 
dihydroceramide desaturase 1, which then converts dihydroceramide to 
ceramide (126). Increases in ceramides, in addition to previously discussed 
activation of JNK, have also been shown to result in decreases in the level of Akt 
phosphorylation (11, 127, 128). Mechanistically, study has suggested this is due 
to an impairment in insulin’s ability to translocate Akt to the PM mediated through 
PKCζ phosphorylation of Akt on its PH domain (129). Other research suggests 
that ceramides activate protein phosphatase 2A, leading to removal of 
phosphorylation of Akt as well as inhibiting PKCλ (130, 131). Importantly, study 
has demonstrated that saturated FA treatment of muscle cells promotes 
macrophage activation, further impinging upon insulin sensitivity (132).  
Recent work in our laboratory has suggested a new role of palmitate-induced 
insulin resistance entailing increased glucose flux through the HBP (discussed 
below) in mediating alterations in PM architecture necessary for glucose 
transport into skeletal muscle (11). In these studies, palmitate treatment was 
found to also promote the characteristic reduction in insulin-stimulated 
phosphorylation of Akt2 and AS160 (11, 127). However, removal of excess PM 
cholesterol using methyl-β-cyclodextrin restored insulin responsiveness despite 
attenuation of insulin signaling at the level of these two key proteins. 
Interestingly, RL2 labeling showed an increase in HBP activity in palmitate 
treated cells that was reversed with HBP inhibition. This is consistent with other 
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reports showing that lipid infusion in rats or palmitate treatment in myotubes 
promotes increased flux through this pathway (133, 134). This increase in HBP 
activity was associated with gains in PM cholesterol content, loss in F-actin 
staining, as well as impaired glucose transport. Strikingly, these PM defects were 
found to be reversed upon HBP inhibition, promoting appropriate glucose 
transport (11). Together, these studies suggest that an important component of 
fat-induced insulin resistance may entail distal signaling derangements that, if 
corrected, could afford protection against insulin resistance.  
 
I.B.2. Glucose and Insulin-induced Insulin Resistance 
Similar to FAs, increases in circulating levels of glucose and insulin are 
known contributors, both in vitro and in vivo, to the exacerbation of insulin 
resistance (8, 9, 12-15, 19, 22, 135-139). As mentioned previously, the 
production of insulin resistance is thought to result in compensatory 
hyperinsulinemia, thereby attenuating hyperglycemia. This line of thought, 
however, implies a primary defect that must initially be responsible for 
hyperinsulinemia itself. Thus, the temporal sequence of events leading to 
pathology is still being elucidated. A review by the late  Dennis McGarry suggests 
that perhaps hyperinsulinemia is the primary defect, thus promoting insulin 
insensitivity and hyperglycemia (140). In fact, the idea of insulin-induced insulin 
resistance in humans is not a recent phenomenon. As early as 1938, Somogyi 
reported that patients who were switched from receiving high doses of insulin to 
low doses had improved insulin sensitivity (141). While complications of high 
dose insulin treatment were initially attributed as bouts of hypoglycemia leading 
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to a rebound hyperglycemia (termed the Somogyi effect), new studies exclude 
this possibility (142) and strongly suggest insulin-induced insulin resistance as 
the mechanism  (143, 144). 
Numerous population-based studies have attempted to discern exactly what 
cutoff should be used to account for hyperinsulinemia in man. In the San Antonio 
Heart Study, fasting and 2 h post-glucose plasma insulin concentrations were 
measured in ~3000 individuals with various insulin sensitivities. In this study, 
hyperinsulinemia was defined in those individuals whose 2 h post-glucose 
plasma insulin concentrations were 2 standard deviations above the mean of the 
non-obese, non-diabetic individuals (135). These levels ranged between 31-700 
µU/ml (186 pM - 4.2 nM). Strikingly, the prevalence of obesity, T2D, 
hypertension, and hypertriglyceridemia were found to be two to three times more 
prevalent in individuals who had insulin levels above 31 µU/ml (186 pM), the low 
cutoff for hyperinsulinemia (145). Mechanistically, cell culture studies have 
clearly demonstrated that chronic exposure to supraphysiological (≥100 nM) 
insulin concentrations induces alterations in the expression and/or activity levels 
of insulin signaling proteins. However, several groups (13, 146), including our 
own (7, 8, 12), have shown that 12-14 hour exposure to more physiologically 
relevant insulin concentrations (500-5000 pM) induces insulin resistance despite 
intact insulin signaling. Rather, this suggests that distal mechanisms in the insulin 
signaling pathway may also become impaired, perhaps at earlier stages in 
disease progression, contributing to the exacerbation of insulin resistance. Within 
that context, work from our laboratory postulates a mechanism involving 
excessive glucose flux through the HBP in provoking PM cholesterol 
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accumulation and a loss in PIP2 regulation of cortical F-actin. The role of the 
HBP in mediating these processes will be the next topic of discussion.  
 
I.B.3. Hexosamine Biosynthesis and Insulin Resistance 
Dating to the 1980’s, it was first discovered that the HBP could modify 
serine/threonine residues of proteins through the addition of the hexosamine β-D-
N-acetyl-glucosamine (147, 148). This highly dynamic modification was found to 
be particularly enriched on transcription factors (149), and coupled to its 
regulation by insulin, excess nutrient bioavailability, and stress, was proposed to 
be a sensor of nutrient overload in the cell (150). Marshall et al. first pioneered 
studies in adipocytes demonstrating that increased routing of glucose through the 
HBP contributed to desensitization of the glucose transport system (151). This 
insight came about serendipitously based on other study that demonstrated that 
treatment of adipocytes with glucose and insulin failed to induce insulin 
resistance when the cells were cultured in a Hepes-buffered salt solution. It was 
identified that the amino acid L-glutamine, a substrate for the rate limiting 
enzyme in the HBP, glutamine:fructose-6-phosphate amidotransferase (GFAT),  
was necessary for modulating the loss of maximal insulin responsiveness (152). 
The first step in glucose entry into the HBP is catalyzed by GFAT, which converts 
fructose-6-phosphate into glucosamine-6-phosphate (GlcN-6-P). GlcN-6-P is 
subsequently metabolized culminating in the production of UDP-N-
acetylglucosamine (UDP-GlcNAc), the high energy substrate of O-GlcNAc 
transferase (OGT), a nuclear and cytosolic enzyme that catalyzes the addition of 
GlcNAc to serine/threonine residues by O-linkage (153, 154). It should be noted 
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that under healthy conditions, the HBP is a relatively minor pathway in the 
utilization of glucose, accounting for only 2-5% of glucose flux. 
 Since the initial discovery that HBP could result in an impairment in insulin 
responsiveness in murine adipocytes, numerous studies have attempted to 
discern the precise role of the HBP in this process. Several subsequent cell 
culture and animal models have clearly demonstrated a role of this pathway in 
the development of insulin resistance (155-159). For instance, overexpression of 
GFAT in liver, muscle, or fat has been demonstrated to impair glucose disposal 
(156, 158, 160, 161). Furthermore, increased HBP activity has been shown to 
promote hyperleptinemia (162), and glucosamine infusion in rats increased 
expression of leptin and resistin, particularly in visceral adipose deposits (163). In 
addition to animal models, polymorphisms in O-GlcNAcase (OGA), the enzyme 
that hydrolyzes O-GlcNAc moieties, have been shown to increase the risk of T2D 
in the Mexican American population (164). In addition, skeletal muscle biopsies 
from T2D patients revealed increases in the mRNA and protein levels of GFAT 
(134, 165). While a large body of research demonstrates HBP-induced insulin 
resistance, the exact mechanisms are incompletely understood. 
 
I.B.4. Hexosamines and the Liver 
 Several studies have provided mechanistic insight into how increased HBP 
activity could promote or exacerbate the insulin resistant phenotype. In the liver, 
in addition to inhibiting gluconeogenesis, insulin also stimulates FA synthesis. In 
insulin-resistant states, selective insulin resistance occurs in which insulin fails to 
signal inhibitory effects on gluconeogenesis while signaling to FA synthesis 
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remains unscathed (36). This, coupled with hyperinsulinemia, can lead to 
dysregulated FA production which can further exacerbate insulin sensitivity. With 
regard to the HBP, study has shown that FOXO1 overexpression reduces the 
activity of the carbohydrate response element binding protein (Chrebp), a key 
regulator of lipogenesis, and that it mediates this process through suppressing O-
linked glycosylation and reducing Chrebp stability (166). In addition, mass 
spectroscopy and subsequent co-immunoprecipitation has revealed PGC-1α is 
modified by O-GlcNAc and that PGC-1α specifically targets OGT to FOXO1, 
mediating its subsequent glycosylation (167). Increased O-GlcNAc of FOXO1 by 
hyperglycemia is, somewhat paradoxically, well established to increase its 
activity toward gluconeogenesis (168). Furthermore, cAMP response element-
binding (CREB) regulated transcription coactivator 2 (CRTC2) also is modified by 
and displays increased O-GlcNAc modification in the diabetic liver (169). 
Normally sequestered in the cytosol through interaction with 14-3-3 proteins, this 
modification promotes its nuclear localization and transcriptional activation of 
gluconeogenesis through binding to CREB. This promotes increases in both 
G6Pase as well as PEPCK (Fig. 2). In this manner, HBP activity is proposed to 
increase gluconeogenesis as well as lipogenesis in the liver, promoting a viscous 
cycle detrimental to insulin sensitivity in fat and muscle.  
 
I.B.5. Hexosamines and the β Cell 
In addition to the liver, HBP activity also has detrimental effects on the β cells 
of the islets. Indeed, streptozotocin, a commonly used treatment to deplete β cell 
mass and recapitulate type 1 diabetes, is known to act through increasing protein
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Figure 2. Schematic of the regulation of gluconeogenesis by the HBP. 
In the liver, insulin signaling to Akt results in the phosphorylation of FOXO1, 
inhibiting its entry to the nucleus and activation of a gluconeogenic program. 
Under conditions of excess glucose flux through the HBP, OGT mediates the 
glycosylation of PGC-1α resulting in the recruitment of OGT toward FOXO1. 
Glycosylation of FOXO1 by OGT promotes an increase in gluconeogenesis. In 
addition, CRTC2 is a known target of OGT. Its modification promotes the 
activation of both gluconeogenic genes as well as PGC-1α (see text for 
expanded details).  
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O-GlcNAc (170). In these studies INS1 cell viability was reduced by nearly 80% 
with 0.1 mg/ml streptozotocin or 5 mM glucosamine for 48 hours. However, other 
study using 0.25-1.0 mM glucosamine for 24 or 48 hours did not observe cell 
apoptosis but rather increased ER stress markers ccaat-enhancer binding protein 
(C/EBP) homology protein (Chop), spliced X-box binding protein 1 (xbp1), and 
activating transcription factor 6 (atf6) (171). This increase in ER stress resulted in 
an impairment in the functionality of the β cells as assessed by oxidative stress 
and the generation of reactive oxygen species (ROS), which resulted in the 
dedifferentiation of the β cell as indicated by a loss of GLUT2, insulin, and 
glucokinase expression (172, 173). Interestingly, transgenic mice that 
overexpress OGA have increased serum insulin and total islet insulin content, 
with increased angiogenesis and Akt activation (174). This supports the notion 
that HBP activity may impart deleterious effects on the β cell by affecting cell 
survival. Taken together, study has demonstrated that HBP activity can be 
particularly toxic to the insulin secreting β cells and may ultimately contribute to 
the failed compensatory response of these cells observed during the 
development of insulin resistance.  
 
I.B.6. Hexosamines and Skeletal Muscle and Adipose Tissue 
The mechanisms whereby elevations in HBP activity provoke insulin 
resistance in skeletal muscle and adipose tissue, however, are less precisely 
understood. In adipocytes and skeletal muscle, study has demonstrated that 
chronic flux through the HBP promotes the targeting of OGT to the PM through 
interaction with phosphoinositides, resulting in attenuation of insulin signaling 
26 
 
(175-177). Published data from our lab suggest increased HBP activity as a basis 
for palmitate, hyperglycemia, glucosamine, and hyperinsulinemia-induced losses 
in insulin responsiveness (7, 11, 19, 22, 178). In these studies, inhibition of the 
HBP with 6-diazo-5-oxo-L-norleucine (DON) protected against the development 
of insulin resistance. Mechanistically, this work established that excess HBP 
activity resulted in a loss of PIP2/F-actin structure at the PM. Concurrently, a gain 
in PM cholesterol content was observed. Interestingly, removal of the excess PM 
cholesterol with methyl-β-cyclodextrin normalized PIP2/F-actin levels and 
restored insulin responsiveness (7). In addition, blockade of the HBP with DON 
inhibited the gain in PM cholesterol and glucose transport dysfunction. One key 
focus of my thesis research was to determine the mechanisms by which HBP 
could promote these perturbations in PM cholesterol content, contributing to the 
development of insulin resistance.  
 
I.B.7. Cholesterol Regulation 
 The maintenance of tightly regulated cholesterol levels is essential for 
cellular function. Approximately 65-90% of cholesterol is found at the PM, 
whereas the remaining 10-35% is found in intracellular membranes (179, 180). 
First identified by Brown and Goldstein, synthesis of cholesterol is primarily 
coupled to the sterol regulatory element binding protein (SREBP) (181). There 
exist three different isoforms of these proteins, SREBP-1a, SREBP-1c, and 
SREBP-2. These factors are known to reside in the endoplasmic reticulum (ER) 
bound in a complex with SREBP cleavage-activating protein (SCAP) and insulin 
inducible gene (Insig). When sterol levels are high in the cell (>5% of total ER 
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lipids), cholesterol binds to SCAP resulting in a conformational change that 
promotes its association with Insig, thereby retaining SREBP in the ER. Under 
conditions of low cholesterol, SCAP/SREBP is transported to the Golgi, where it 
is cleaved by proteases into its active form. This active form is then translocated 
to the nucleus where it can activate transcription of genes involved in cholesterol 
synthesis, such as HMG-CoA reductase (HMGR), the rate-limiting enzyme in 
cholesterol synthesis. This activation can also promote an increase in the levels 
of the low density lipoprotein (LDL) receptor, thereby promoting cholesterol 
uptake from the environment. In addition to regulation by cholesterol, insulin is 
known to promote the activation of SREBP proteins through increasing the 
degradation of mRNA encoding Insig (182). In this manner, the total amount of 
Insig protein can become rate-limiting with regard to the retention of 
SCAP/SREBP in the ER (183). Further, insulin stimulation can also result in the 
phosphorylation of SREBP, increasing the affinity of the SREBP/SCAP complex 
for Sec23/24 proteins of coat protein complex II (COPII) vesicles and thereby 
promoting transport to the Golgi for cleavage (182).  
Extending beyond SREBP, HMGR activity is also known to be regulated 
through its direct binding to SCAP. However, dissimilar to SREBP retention, 
during high levels of sterols, complex formation between HMGR and Insig in the 
ER promotes the ubiquitination and subsequent proteasomal degradation of 
HMGR (184). It should be noted that these methods of cholesterol regulation are 
primarily mediated by SREBP-2, yet SREBP-1 plays a role in cholesterol 
synthesis. Transgenic mice overexpressing SREBP-1a, for instance, have a 37 
fold increase in expression of HMGR in liver compared to wild-type mice (185-
28 
 
187). In addition, SREBP1c, known to play a minor role in cholesterol synthesis, 
has increased expression in response to insulin in liver, fat and skeletal muscle 
(188-191).  
 In addition to regulating synthesis and uptake of cholesterol through the 
environment, cells are also able to mediate cholesterol efflux processes to 
moderate cholesterol levels. This process involves the ATP-binding cassette 
transport proteins (ABCA1 and ABCG1) (192-194). The ABCA1 transporter is 
known to promote unidirectional transport of free cholesterol to lipid-poor 
apolipoprotein (ApoA-I), forming pre-β-1 HDL. After forming this subparticle, the 
enzyme lecithin-cholesterol acyltransferase (LCAT) can esterify this free 
cholesterol generating the mature pre-β-2 or α-HDL particles (195). In contrast to 
ABCA1, ABCG1 is less specific and can efflux cholesterol to more mature HDL 
particles or even LDL particles (196). The synthesis of these transporters is 
reported to occur when there is an elevation in cholesterol synthesis 
intermediates or oxysterols, oxidized derivatives of cholesterol. This results in an 
activation of the liver X receptor (LXR) which can heterodimerize with the retinoic 
X receptor (RXR) and bind to LXR response element sequences in DNA to 
promote the transcription of ABCA1 other cholesterol transporters (197-200). In 
addition to cholesterol efflux, adipose tissue is capable of storing large amounts 
of non-esterified cholesterol. In fact, it is estimated that approximately 50% of 
cholesterol is stored in fat tissue with obesity (201). While these mechanisms 
tightly regulate cholesterol levels, study strongly suggests that cholesterol can 
become deregulated, leading to insulin resistance.   
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I.B.8.  The HBP and Cholesterol Dysregulation  
 A primary component of my thesis work was the attempt to determine how 
hyperinsulinemia, through engaging the HBP, could promote cholesterol 
dysregulation despite several of the numerous regulatory processes described in 
the previous section. Study by the late Jeffrey Kudlow elucidated that the HBP 
induces O-GlcNAc on specificity protein 1 (Sp1), a key transcription factor 
involved in cholesterol synthesis (202). While normally a ubiquitous transcription 
factor that recognizes a GC box in the promoter of TATA-less genes (203, 204), 
this modification is thought to specifically target Sp1 to genes involved in 
metabolic processes. Much like the effect of this modification on other proteins, 
O-GlcNAc of Sp1 increases its stability and promotes its nuclear translocation 
(202, 205). It should be noted that phosphorylation of Sp1 on PEST sequences, 
(sequences rich in Pro, Glu, Ser, and Thr), targets Sp1 for degradation and that 
O-GlcNAc may occur on these same sequences, suggesting that O-GlcNAc may 
oppose the actions of phosphorylation on protein regulation (206). In terms of 
cholesterol synthesis, Sp1 GC binding motifs are known to be present adjacent 
to sterol response elements (SRE) (207, 208). The promoter of the SREBP1 is 
known to contain 5 Sp1 binding sites which, in conjunction with SREBP1 itself as 
well as LXR and NF-Y drive its maximal expression (209-212). Interestingly, a 
Sp1-like binding site has recently been proposed in the promoter region of 
HMGR (213, 214). In this context, O-GlcNAc on Sp1 could potentially result in 
increases in SREBP1 and HMGR through increasing their promoter activity. 
Further, increases in SREBP1 could also increase HMGR as it binds to a SRE in 
the promoter of HMGR. An additional recent finding is that LXR is also a target of 
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O-GlcNAc, with evidence suggesting the modification of this protein drives 
SREBP1 expression (215). Furthermore, histone H2B was also recently identified 
as a target of O-GlcNAc, driving increased expression of numerous metabolic 
genes including HMGR (216) In this context, my thesis work sought to determine 
the mechanism by which O-GlcNAc on Sp1 by hyperinsulinemia could modify its 
activity as well as provoke a cholesterolgenic response. Of interest is whether 
inhibition of Sp1 and/or its modification could prevent against the development of 
an insulin resistant phenotype.  
 
I.B.9.  Lipoprotein Metabolism and Insulin Resistance 
Insulin resistance and metabolic syndrome are closely associated with 
dyslipidemia and alterations in circulating as well as cellular cholesterol levels. 
Specifically, insulin resistance often presents with high circulating levels of LDL 
(>100 mg/dl) and low HDL (<40 mg/dl). These findings suggest that insulin 
resistance is tightly coupled to alterations in lipoprotein metabolism. A focus of 
my thesis research aims to determine how hyperinsulinemia may promote 
alterations in the generation of HDL in adipocytes. While adipose tissue is 
primarily considered a cholesterol sink, reverse cholesterol transport (RCT) from 
this tissue in insulin resistant states may substantially contribute to whole body 
cholesterol homeostasis. In addition, parallel experiments with macrophages 
demonstrate very similar rates of ABCA1-mediated cholesterol efflux from these 
cells to ApoA1 (217). Mechanistically, ABCA1 trafficking to the membrane is 
facilitated by the endosomal membrane (EM) to cytosolic cycling of Rab8 in 
adipocytes (218). In the context of hyperinsulinemia-induced dysregulation of 
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cholesterol synthesis, increased endosomal cholesterol content could impair the 
ability of Rab8 to be extracted from the endosomal membranes by guanine 
nucleotide dissociation inhibitor (GDI). In fact, in patients with Niemann-Pick 
Disease, Type C (NPC), elevations in EM cholesterol promote the sequestering 
of ABCA1 (219). Additionally, Cr3+ supplementation in brewer’s yeast has also 
been shown in some human trials to be necessary for the maintenance or even 
improve HDL levels (220, 221).  
Extending beyond adipose tissue, cholesterol efflux transporters are known 
to play a vital role in the maintenance of cholesterol regulation in the β cells. 
Study has previously shown, for instance, that inactivation of the ABCA1 
transporter in these cells promotes cholesterol accumulation in secretory vesicles 
and abrogates glucose-stimulated insulin secretion (222). Further, loss of ABCG1 
has been shown to alter insulin granule morphology, cholesterol levels, and lead 
to impaired insulin secretion (196). In mouse models of diabetes and 
dyslipidemia, increases in islet cholesterol content have been observed, 
suggesting a potential but important role of the precise regulation of cellular 
cholesterol content in the maintenance of  glucose sensing and insulin secretion 
(223). In this regard, depletion of cholesterol content in the β cells using a 
squalene epoxidase inhibitor, NB598, or methyl-β-cyclodextrin impaired glucose-
stimulated insulin secretion (224, 225), yet treatment with lovastatin has been 
shown to result in impaired regulation of insulin secretion as indicated by 
constitutive basal secretion (226). Together, the role of Cr3+ action on improving 
lipoprotein metabolism is currently poorly understood. The following subsection 
will cover a brief history of Cr3+ and its impact on glucose and lipid metabolism in 
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health and disease. It will also outline several proposed mechanisms for Cr3+ 
action in adipose and skeletal muscle tissue.  
 
I.C. Chromium Supplementation in Health and Disease 
The case for Cr3+ as beneficial in the maintenance of healthy glucose 
metabolism was first established in 1957 when Schwarz and Mertz discovered a 
concentrate from brewer’s yeast that improved glucose tolerance in Sprague-
Dawley rats (227). While initially deemed a glucose tolerance factor, its isolation 
and identification as Cr3+ was determined just two years later (20, 228). Shortly 
after its identification, it was determined that the site of action of this nutrient was 
the plasma membrane. Initially, autopsy results demonstrated that Cr3+ levels 
severely declined in tissues with age, particularly in the heart where it was 
reduced by greater than 95% by age 20 (229). This finding ultimately led to the 
hypothesis that chromium deficiency could promote the development of 
atherosclerosis. Indeed, decades later Cr3+ deficiency is known to promote 
increases in serum cholesterol, triglycerides, and decreased levels of HDL (221, 
230, 231). In humans, even after its discovery, trivalent Cr3+ was still universally 
considered a toxic carcinogen, although less so than hexavalent Cr6+. This notion 
disappeared when it was recognized that the biologically essential trivalent form 
could not be oxidized in living organisms to the carcinogenic hexavalent form 
(228). Yet the essentiality of Cr3+ was still heavily debated due to the fact that 
Alan Walsh’s invention of atomic absorption, used to detect intestinal Cr3+ 
absorption, placed the rate at close to zero. As analytical methods improved, 
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however, the essentiality of Cr3+ in animals for optimal glucose and lipid 
metabolism became accepted. 
In 1977, Cr3+ was declared as an essential nutrient for humans when a 
woman receiving total parenteral nutrition (TPN) devoid of Cr3+ presented to a 
physician with severe weight loss, peripheral neuropathy, and hyperglycemia 
(232). An intravenous glucose tolerance test on this patient confirmed that she 
was glucose intolerant. Administration of 45 units of insulin was required to 
maintain plasma glucose values at normal ranges, although this amount of 
insulin did not mitigate the glucose intolerance. Based on emerging evidence that 
chromium deficiency could provoke glucose intolerance, levels of chromium in 
the blood and hair were assessed and it was determined that there was 
approximately a 90% reduction in the levels compared to normal values. 
Subsequent addition of Cr3+ to the nutrition regimen over the course of several 
weeks resulted in a significant potentiation of insulin’s action on glucose 
tolerance and reduced the amount of insulin required in this patient to 15 units.   
Since then, numerous studies have shown a beneficial effect of Cr3+ on at 
least one parameter of glycemia in humans (233-238). Furthermore, a recent 
systematic review of the randomized control trials with chromium found that 
chromium improved glycosylated hemoglobin as well as fasting glucose (23). The 
authors conclude based on the current research that chromium may have 
modest effects on glucose sensitivity. They do, however, point out that of the 
trials that found no significant effect of chromium, nearly half of them were poorly 
controlled and/or statistically underpowered. Since the benefit of chromium 
treatment could also be masked in patients taking medications, this could 
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suggest a more than modest effect of chromium on patients. Of note, a majority 
of these findings were conducted in patients with T2D. Study by Richard 
Anderson, who observed large benefits of chromium in patient populations, 
witnessed an absence of a beneficial effect in individuals with normal glucose 
tolerance (239). In fact, an increase in 90 minute post-load glucose levels was 
seen in these patients. However, another study of the short term effects of 
chromium in overweight children found a significant improvement in HOMA (240). 
Complicating interpretation further, study by William Cefalu has suggested that 
patient phenotype is important in the clinical response to chromium 
supplementation (234, 241). Clinically, a parameter has not yet been determined 
to assess patients who have a low chromium status (to be discussed below). 
However, a future direction suggested of clinical trials is to delineate precisely 
what patient populations would benefit from supplementation, providing 
individualized care (242). Furthering this endeavor will undoubtedly require 
mechanistic details into the actions of chromium to better understand what 
metabolic abnormalities that present in patients could be best amendable to 
chromium therapy.  
 
I.C.1. Chromium Balance and Insulin Resistance 
An important consideration with regard to human studies is the precise 
amount of chromium needed to evoke a physiological response. As such, a 
wealth of studies have been conducted with regard to the bioavailability of 
chromium as well as the daily requirements. As recommended by the Food and 
Nutrition Board of the Institute of Medicine of the National Academy of Sciences, 
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the adequate intake of chromium is set to 30 µg/d (243). Given the known 
absorption of chromium at approximately 0.5%, this presents 0.15 µg to the 
bloodstream per day. Retrospectively, this indicates that in cases like the woman 
presented above receiving total parenteral nutrition devoid of chromium, the 
amount of chromium delivered was perhaps “adequate”. As John Vincent 
describes, given the concentrations in the TNP that were provided, the solutions 
ranged from 2-6 µg/d. While initially considered devoid, the intravenous diet 
ensured that all of the chromium was delivered into the bloodstream, meaning 
that patients were actually receiving more than the 0.15 µg/d that is considered 
adequate (232, 244-246). In addition, the levels of chromium added back to the 
TPN were actually 125-250 µg/d, a pharmacological dose. In humans, studies 
have provided at maximum a dose of 1 mg/d. Based on safety recommendations 
stating that up to 10 mg/day of chromium would be expected to have no health 
risks, the need for clinical trials aimed at using higher doses of chromium for long 
periods of time while carefully monitoring for adverse risks would greatly benefit 
clinical trials. 
In this regard, there are several different forms of chromium commercially 
available. These include chromium yeast (CrY), chromium chloride (CrCl3), and  
chromium picolinate (CrPic), the most stable form (247). Recent other 
pharmacological chromium complexes known to exert beneficial effects on 
glucose and lipid metabolism have also been generated, including chromium 
nicotinate/niacin (CrN), chromium (D-phenylalinine3), and chromium citrate 
(CrCIT) (248-250). While CrPic is popularized because of its known greater 
absorption (251), coupled to its increased excretion, its bioavailability is not 
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thought to be greater than other forms available (251, 252). Nevertheless, it 
retains its popularity, as CrPic containing supplements are currently ranked 
second in sales among mineral supplements after calcium (253).  
 In the context of insulin resistance, it is known that alterations occur in the 
urinary excretion of chromium. In fact, in non-insulin resistant type 1 diabetic 
children, study has shown decreased plasma, erythrocyte and urine chromium 
compared to non-diabetic control individuals (254). In another study, increased 
insulin resistance in non-diabetic Saudi adults was highly correlated with 
increased excretion of chromium in the urine, suggestive of chromium deficiency 
(255). In diabetic rats, which also demonstrated increased urinary chromium loss 
as a result of diabetes, there is also a compensatory increased absorption which 
is thought to balance chromium status, again suggesting that beneficial effects of 
chromium may not come from alleviating chromium nutritional deficiency but 
rather supplementation at pharmacological doses  (256). Nevertheless, some 
studies still suggest that the typical western diets do not provide enough 
chromium for the adequate daily intake requirement (247, 257-259), so the 
possibility that a deficiency exists that could be amendable to replacement 
cannot be discredited.  
 
I.C.2. Cellular and Mechanistic Details of Chromium Action 
Several mechanisms have been proposed to explain the details of 
chromium’s effect on potentiating insulin action. For example, chromium has 
been shown in studies increase insulin binding to its receptor, the number of 
receptors, and also receptor phosphorylation and activation (260-262). Studies 
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have demonstrated that chromium is transported in the circulation bound to 
siderophilin (transferrin) or albumin, although >90% is proposed to be bound to 
transferrin (263-266). Although transferrin exhibits strong selectivity for iron (III) 
ions based on its binding sites, in humans the protein has been shown to 
normally be 30% saturated with iron (267). UV spectra analysis has subsequently 
demonstrated that chromium can bind to two metal sites in transferrin (268-271). 
The binding of chromium to transferrin has been shown biochemically to be quite 
strong, with an effective binding constant of 2.92 x 1015 M-2 (267). Upon 
endocytosis of transferrin by the cell, it must then be transferred from the 
endosome to the cytosol. Unlike iron, which is reduced and transported to the 
cytosol by divalent metal transporters, chromium is not readily reduced and the 
mechanistic details of its transport are currently a topic of future investigation.  
With regard to transferrin’s ability to transport both iron and chromium, a 
recent Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study in 
humans has associated increased levels of total iron, serum ferritin (the primary 
means of iron storage), and non-transferrin-bound iron with adipocyte insulin 
resistance, measured as the product of fasting insulin and nonesterified FAs 
(272). In another human study, it was found that circulating serum soluble 
transferrin receptor levels were inversely correlated with insulin sensitivity in 
normal glucose tolerant, non-obese subjects (273). Interestingly, however, in 
humans with T2D there is a reported loss in the serum levels of chromium 
compared to nondiabetic control subjects (274). Together, these studies suggest 
that, even if deficiencies are not present, alterations in the balance of circulating 
chromium and iron levels could contribute to the pathology of insulin resistance.  
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Upon entering the cell, chromium is known to bind the low-molecular-weight 
chromium binding substance (LMWCr, chromodulin). It has been suggested that 
this response is mediated by the action of insulin on the insulin receptor (275, 
276). Upon binding of chromium to chromodulin, this complex then binds to the 
receptor and has been suggested to maintain the receptor in its active 
conformation, thereby amplifying the signaling cascade (246). Further study 
needs to be conducted to elucidate the exact biochemical mechanism of this 
response. In addition, little is known about the regulation of the formation of this 
chromodulin complex, a necessary topic of future research.  
In addition to reports suggesting that chromium may improve the ability of 
insulin to stimulate glucose transport into adipose and skeletal muscle tissue 
through modulation of insulin signaling, work in our lab and others suggests 
chromium may positively influence PM parameters including membrane fluidity 
(21, 277). Furthermore, moderate increases in PM fluidity have previously been 
shown to increase glucose transport (278-280). Consistent with this hypothesis, 
reductions in membrane fluidity have been shown to impair glucose transport 
(279). In our adipocyte studies chromium was found to diminish excess PM 
cholesterol content, concomitant with an increase in the redistribution of GLUT4 
to the PM. This event was lost in the presence of exogenously added cholesterol, 
strengthening the hypothesis that alterations in PM cholesterol contribute to 
chromium’s action. Interestingly, insulin-stimulated glucose transport was not 
enhanced by chromium treatment. However, in cells treated with chromium in the 
presence of insulin, there was a significant increase in glucose transport. None of 
these observed effects were associated with amplification of insulin signaling. 
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Whereas these studies were performed in cells cultured in high glucose 
conditions (25 mM glucose), chromium did not have an effect on the 
redistribution of GLUT4 to the PM in cells cultured in non-diabetic (5 mM 
glucose) conditions (22). Recent studies in our lab also demonstrate that 
chromium does not improve glucose uptake in L6 myotubes grown under non-
diabetic conditions. However, when cells were treated with pathophysiologic 
hyperinsulinemia (5 nM, 12 h) in the presence of CrPic (100 nM, 16 h), chromium 
restored insulin responsiveness and corrected hyperinsulinemia-induced 
cholesterol accrual. Taken together, this data strongly suggests a beneficial 
effect of chromium on membrane parameters through altering PM cholesterol 
content.  
 
I.C.3.  AMPK and Chromium Action 
Mechanistically, recent study suggests that a target of chromium action 
entails activation of 5’ AMP activated protein kinase (AMPK) (19, 281). 
Furthermore, knockdown of AMPK was demonstrated by our lab to negate the 
beneficial effects of chromium on GLUT4 translocation and glucose uptake in 
hyperinsulinemic cells (unpublished data). These studies demonstrated that an 
80% knockdown of AMPK in transfected cells resulted in a loss in chromium’s 
ability to phosphorylate and activate of AMPK as observed in scramble 
transfected cells. Additionally, insulin signaling was intact in the knockdown cells 
and chromium’s mode of action did not involve amplification or correction of 
insulin signaling defects. Rather, they strongly suggest that chromium, through 
engaging AMPK, may inhibit cholesterol accrual. In addition, elevations in 
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membrane cholesterol were also observed in C57Bl/6J mice fed a HF diet, 
whereas chromium supplementation in these animals restored cholesterol 
content concomitant with a recovery in glucose and insulin tolerance. These 
studies are of interest in the context that AMPK is known to result in the 
phosphorylation and inactivation of HMGR. This observation could potentially 
explain the mitigation in cholesterol accumulation at the PM observed in cells 
pretreated with chromium. 
Of note, AMPK has been referred as a fuel gauge sensing low energy status 
(282-287). This occurs when the cell has depleted high energy molecules such 
as 5’ adenosine triphosphate (ATP), resulting in an increase in the AMP/ATP 
ratio. In the absence of AMP, the complex exists in an inactive conformation and 
the α and γ subunits do not directly interact. In this form, the active site cleft is 
blocked, preventing upstream kinases from phosphorylating an important 
activating threonine 172 residue. When AMP accumulates in the cell, it can 
directly bind between the α and γ subunits at a cystathionine-β-synthase (CBS) 
domain, exposing the threonine site for activation (288). In this manner, AMP 
binding promotes a conformational change in the α catalytic subunit, rendering it 
susceptible to upstream kinase targeting on threonine 172, thereby triggering its 
activation (289-291). Two kinases have been proposed to activate AMPK in this 
way, including liver kinase B1 (LKB1) (292-294) and calmodulin-dependent 
protein kinase β (CaMKKβ) (295-297). Indeed, phosphorylation at this residue 
has been shown to be essential for kinase activity and serves as a good marker 
to assess the activity of the kinase (291, 298, 299). In addition to inhibiting 
HMGR, numerous studies have shown that AMPK activation regulates enzymes 
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essential for FA metabolism by phosphorylation of acetyl-CoA carboxylase (ACC) 
on serine 79, thereby attenuating the production of malonyl-CoA, a key 
intermediate in FA synthesis (300-308). In this manner, chromium treatment, 
through activation of AMPK, might work in the cell to promote energy producing 
pathways while simultaneously inhibiting those anabolic processes such as 
cholesterol and FA synthesis.  
While AMPK regulation was not a major focus of my doctoral research, the 
role of AMPK in energy conservation and inhibition of HMGR activity is of 
interest. In stark juxtaposition to the HBP, a sensor of excess energy 
bioavailability within the cell, AMPK activity signals energy conservation 
pathways. As anticipated, research has recently suggested a crosstalk between 
these two pathways as AMPK is a known target of OGT and AMPK has also 
been shown to phosphorylate and inhibit GFAT (309-311). This finding is of 
significance as it suggests pleiotropic actions of chromium on preventing PM 
cholesterol accrual that impairs insulin action. As such, a hypothesis of my thesis 
research is that chromium may inhibit transcriptional responses promoting 
cholesterol synthesis, thereby restoring insulin responsiveness. The effects of 
chromium on these parameters were tested mechanistically in vitro in the context 
of hyperinsulinemia-induced activation of the HBP. In addition, as C57Bl/6J mice 
suggest increased HBP as a mechanism fueling insulin resistance, study sought 
to validate in vitro findings and delineate the mechanistic aspects of chromium 
treatment in vivo. The following subsection gives a brief report of the clinical 
relevance of this work in the context of current diabetes treatment options.  
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I.D. Clinical Perspectives 
As aforementioned, the prevalence of T2D and its deleterious effects on the 
quality of life for patient populations represents a global health concern. 
Currently, 6.4% of the world population has T2D, and it is estimated that in the 
next 20 years the prevalence will grow by over 20% (312). While a major genetic 
basis exists for the development, the recent surge in prevalence underscores the 
influence of lifestyle, environmental, and technological factors in contributing to 
the diagnosis and prevalence of disease. While diet and exercise are proposed 
to strongly prevent the development of disease, patient compliance is a major 
fundamental challenge. In this regard, the use of pharmacological chromium for 
certain patient populations may help alleviate the burden of T2D. While clinical 
studies suggest a beneficial effect primarily in T2D, the modest effect of 
chromium could be masked by the effects of other antihyperglycemic drugs. For 
instance, several agents that normalize blood glucose concentrations, improve 
insulin action, or improve metabolic syndrome including metformin (313-315), 
rosiglitazone (316), troglitazone (317), exendin-4 (318), glucagon-like peptide 1 
(GLP1) (319), miglitol (320), and atorvastatin (321) are reported to activate 
AMPK. In addition to these, numerous nutritional supplements are also shown to 
activate AMPK, including berberine (322-324), triterpenoids (325), and 
resveratrol (326-329).  
While many studies have examined the potential of therapeutic targets on 
activation of AMPK, few have focused attention on whether any inhibit the HBP 
activity. Of particular interest, however, was a study which found that treatment of 
adipocytes with troglitizone or rosiglitazone inhibited HBP activity induced by 
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glucosamine treatment (330). Strikingly, treatments with these thiazolidinediones 
(TZDs) did not inhibit global O-GlcNAc, but specifically inhibited increased 
modification of Sp1, thereby reducing the expression of the adipokine, resistin 
(331). Taken together, these findings suggest that repression of HBP-induced 
modification of the activity of Sp1 might represent a therapeutic target that could 
potentially alleviate insulin resistance. These findings also underscore the 
importance of gaining further understanding of the mechanisms by which 
increased activation of the HBP and subsequent Sp1 modification may provoke 
insulin resistance in the context of our findings that PM cholesterol accrual may 
represent a key derangement contributing to insulin resistance. 
 
I.E. Thesis Hypothesis and Specific Aims 
Based on the fundamental research findings presented above and the 
current gap in the understanding of transcriptional mechanisms leading to 
cholesterol accrual and actions of chromium, I formulated the following 
hypotheses for my thesis research. My central hypothesis is that 
hyperinsulinemia-induced elevations in the HBP activate a cholesterolgenic 
response by modulation of critical transcription factors involved in the regulation 
of cholesterol synthesis. Furthermore, I predict that the beneficial effects of 
chromium on glucose and cholesterol homeostasis will be mediated through an 
inhibitory effect on HBP-induced cholesterol accrual. Using cellular and animal 
models of insulin resistance, I tested my central hypothesis by pursuing the 
following two specific aims: 1) Dissect the transcriptional mechanisms of aberrant 
cholesterol synthesis promoting insulin resistance and 2) Delineate the protective 
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actions of chromium supplementation on the HBP and cholesterol efflux 
processes.  
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Chapter II. Results 
 
II.A. Increased HBP Activity Provokes Cholesterol Synthesis, 
Cytoskeletal Dysfunction, and Insulin Resistance via Transcriptional 
Activation of Sp1 
 
II.A.1. Summary 
Increased caloric intake and/or obesity are currently the greatest 
predisposing risk factors for the development of T2D. Recent study implicates 
increased nutrient flux through the HBP as an underlying basis for the 
development and exacerbation of insulin resistance and β cell failure, hallmark 
events in the pathology of T2D. Nevertheless, the precise mechanistic insight 
into how excessive HBP flux contributes to the desensitization of the glucose 
transport system is currently unknown. Previous study has demonstrated that 
hyperinsulinemia-induced increases in HBP activity resulted in PM cholesterol 
accumulation and insulin resistance in 3T3-L1 adipocytes. Here, we tested the 
effects of increased HBP activity on provoking a transcriptional cholesterolgenic 
response involving the modification of Sp1, potentially promoting increases in its 
binding affinity and activity toward promoter regions of SREBP1 and HMGR. In 
3T3-L1 adipocytes, varying low, pathophysiological doses of insulin (250 pM - 5 
nM) for 12 h promoted increased PM cholesterol as well as HMGR 
mRNA/protein. SREBP1 was increased under these conditions, both in its 
inactive and active, nuclear forms. O-GlcNAc modification of Sp1 was elevated in 
cells treated with hyperinsulinemia, whereas HBP inhibition with DON protected 
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against this effect. This modification of Sp1 was associated with a greater affinity 
of this transcription factor toward the promoter of HMGR and SREBP1. 
Luciferase assays confirmed that this increase in binding resulted in activation of 
the promoter. Treatment with DON prevented against these alterations as well as 
the increased mRNA/protein content of HMGR. Consistent with the role of Sp1 in 
mediating these effects, the Sp1 DNA-binding inhibitor, mithramycin, completely 
rescued increased HMGR protein, PM cholesterol, F-actin loss, and glucose 
transport dysfunction. These data suggest a possible mechanism whereby the 
modern lifestyle, abundant in excess nutrient intake, may impinge on glucose 
transport and contribute to the development of T2D.  
 
II.A.2. Results 
 
Pathophysiological Hyperinsulinemia Provokes Cholesterol Synthesis: 
Studies have demonstrated that hyperinsulinemia induces cellular insulin 
resistance via increased PM cholesterol content, in turn reducing cortical F-actin 
necessary for distal components of GLUT4 translocation (7, 11) As 
pathophysiological hyperinsulinemia has been defined as levels of insulin 
between 186 pM and 4.2 nM (135), it was probed whether low doses of insulin 
would increase PM cholesterol content in 3T3-L1 adipocytes. Overnight exposure 
of cells to 250 pM, 500 pM, and 5 nM insulin resulted in a 20%, 45% and 43% 
increase in PM cholesterol, respectively, compared to control cells (Fig. 3A). 
While all 3 doses significantly increased PM cholesterol, the 500 pM and 5 nM 
doses resulted in increases that were significantly different than that observed 
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with the 250 pM dose of insulin. The effects of these doses of chronic insulin on 
the status of HMGR were next assessed. Consistent with hyperinsulinemia 
modulating the transcriptional activity of the gene, 250 pM, 500 pM and 5 nM 
insulin all increased the mRNA expression of Hmgcr, encoding HMGR (Fig. 3B). 
This was consistent with an observed gain in HMGR protein levels in cells 
exposed to 500 pM and 5 nM, but not 250 pM insulin (Fig. 3C). As HMGR is 
known to be regulated by SREBP1 and SREBP2, total levels of these proteins 
were examined. Treatment with 500 pM and 5 nM insulin resulted in an 80% 
increase in total SREBP1 content (Fig. 3D). SREBP2 protein content was 
unaffected by any of these treatments. In all of these experiments, the 500 pM 
dose of insulin had the same effect as the 5 nM dose. As such, all subsequent 
studies utilized this dose to examine the effects of the HBP on cholesterol 
synthesis.  
 
Hyperinsulinemia Engages the HBP to Promote O-linked Glycosylation 
of Sp1: It has been previously documented that flux through the HBP increases 
O-GlcNAc of Sp1 (332). Study next sought to determine if hyperinsulinemia 
resulted in an increase in modification of this protein. Immunoprecipitates of Sp1 
from insulin-treated adipocytes displayed a marked increase in O-linked 
glycosylation compared to control cells (Fig. 4A). In contrast, concurrent 
treatment with the HBP inhibitor DON completely prevented against this elevation 
in Sp1 O-GlcNAc. In addition, treatment with DON had no effect on this 
parameter in control cells. To test the sensitivity of the RL2 antibody in detecting 
changes in glycosylation status of Sp1, a Click-iT O-GlcNAc enzymatic labeling 
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Figure 3. Pathophysiological hyperinsulinemia provokes a cholesterolgenic 
response. 3T3-L1 adipocytes were treated with or without 250 pM, 500 pM, or 5 
nM insulin for 12 h. PM cholesterol content (A) was assessed and normalized to 
total PM protein content. Mean values ± SEM are shown from 4 independent 
experiments. *, P<0.05 versus control. #, P<0.05 versus 250 pM insulin. The 
mRNA content of Hmgcr (B) was also determined and normalized to 36B4. 
Means values ± SEM are shown from 8-9 independent experiments. *, P<0.05 
versus control. Protein levels of HMGR (C) were determined by immunoblotting, 
normalized to actin. Mean values ± SEM are shown from 6 independent 
experiments. *, P<0.05 versus control. Total protein levels of SREBP1 (D) were 
also determined by immunoblotting, normalized to actin. Mean values ± SEM are 
shown from 3 independent experiments. *, P<0.05 versus control.  
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system was used for a more sensitive detection of the hyperinsulinemia-induced
and DON-inhibited increases in O-GlcNAc modification. While the trends 
observed were similar, the Click-iT kit revealed an approximate 3 fold increase in 
modification of Sp1 with hyperinsulinemic conditions (Fig. 4B). While O-linked 
glycosylation has been observed to promote an increase in its nuclear 
localization, nuclear Sp1 was not elevated with hyperinsulinemia, consistent with 
other reports that this factor is mainly localized to the nucleus (149, 333). 
However, hyperinsulinemia did result in a 54% increase in SREBP1 content in 
nuclear fractions (Fig. 5). Consistent with the HBP provoking this gain in nuclear 
SREBP1, DON treatment strongly trended (P=0.07) to prevent this increase. 
HBP inhibition had no effect on localization of SREBP1 under control conditions.  
 
Hyperinsulinemia-induced O-GlcNAc of Sp1 Increases its Binding 
Affinity: To determine if elevated glycosylation of Sp1 induced by 
hyperinsulinemia resulted in the transactivation of cholesterolgenic genes such 
as Srebf1, encoding SREBP1 and Hmgcr, encoding HMGR, chromatin 
immunoprecipitation (ChIP) was performed. As previous studies have identified 
that many SRE responsive genes contain binding sites for Sp1, including Srebf1, 
the binding affinity of Sp1 toward this promoter was first examined (207, 208, 
334, 335). Results from these assays revealed that hyperinsulinemia treatment 
induced an approximate 2 fold increase in the binding affinity of Sp1 toward the 
promoter region of SREBP1 (Fig. 6). In control cells, very little binding was 
detected and DON did not affect this affinity. However, the hyperinsulinemia-
induced increase in Sp1 binding toward the promoter was abrogated by blocking 
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Figure 4. Hyperinsulinemia provokes O-linked glycosylation of Sp1.  
3T3-L1 adipocytes were pretreated with or without 20 µM DON for 16 h. After 4 h 
of pretreatment, cells were treated with or without 500 pM insulin for 12 h. 
Following treatments, lysates were prepared and immunoprecipitated with an 
Sp1 antibody. Eluted samples were then immunobloted with an RL2 antibody (A) 
to detect O-linked glycosylation of Sp1. The glycosylation of Sp1 was normalized 
to an input sample of Sp1 from lysed samples. Means values ± SEM are shown 
from 4 independent experiments. *, P<0.05 versus control. Immunoprecipitates 
prepared as described above were subjected to enzymatic labeling with a Click-
iT kit and immunobloted with a streptavidin (Stp) antibody (B). Means values ± 
SEM are shown from 3 independent experiments. *, P<0.05 versus control.  
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Figure 5. Hyperinsulinemia provokes nuclear localization of SREBP1. 
3T3-L1 adipocytes were pretreated with or without 20 µM DON for 16 h. After 4 h 
of pretreatment, cells were treated with or without 500 pM insulin for 12 h. 
Following treatments, nuclear fractions were prepared from lysates. Nuclear 
extracts were then immunoblotted with an antibody for SREBP1. The total 
nuclear content of SREBP1 was normalized to Ponceau staining. Means values 
± SEM are shown from 4 independent experiments. *, P<0.05 versus control.  
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the HBP with DON. Interestingly, an Sp1-like binding site in the promoter region 
of HMGR has also been observed (213). ChIP analyses were thus conducted to 
assess the binding affinity of Sp1 toward this promoter under these conditions. 
Similarly, basal binding of Sp1 to HMGR was minimal, yet hyperinsulinemia 
demonstrated a 4 fold increase in the binding of Sp1 toward this promoter (Fig. 
7). This effect was lost upon concurrent treatment with DON.  
 
Hyperinsulinemia Promotes the Transcriptional Activation of HMGR: 
Since the transcriptional regulation of SREBP1 by Sp1 has been studied 
extensively (210, 211, 336), whereas regulation of HMGR by Sp1 is incompletely 
understood, study sought to determine the role of the Sp1 binding site in the 
promoter region of HMGR. Specifically, it was sought to determine how 
hyperinsulinemia, which provoked an increase in binding of Sp1 toward the 
promoter, affects the activity of this promoter. Plasmids which contained the 
coding sequence of HMGR coupled to luciferase (Fig. 8A) were electroporated 
into 3T3-L1 adipocytes and luciferase assays were performed after treatments. 
This promoter region was determined to contain the 3 consensus binding sites 
for Sp1 that were determined by in silico analysis using MatInspector (Fig. 8B). 
In cells chronically exposed to 500 pM insulin, the activity of the promoter region 
of HMGR was found to be elevated by approximately 50% compared to control 
cells (Fig. 8C). Consistent with the ChIP data showing a reduction in Sp1 binding 
to the promoter when cells were treated with hyperinsulinemia in the presence of 
DON, the increased luciferase activity was corrected with DON treatment. 
Together, these results suggest that hyperinsulinemia-induced O-linked
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Figure 6. Hyperinsulinemia increases Sp1 binding to the promoter of 
SREBP1. 3T3-L1 adipocytes were pretreated with or without 20 µM DON for 16 
h. After 4 h of pretreatment, cells were treated with or without 500 pM insulin for 
12 h. Following treatments, DNA was sonicated and ChIP was performed using 
an Sp1 antibody. Purified DNA and primers specific to the Sp1 binding site in the 
promoter region of SREBP1 were utilized for qPCR analyses. Ct values from 
qPCR were normalized to the background IgG antibody using the fold enrichment 
method. Means values ± SEM are shown from 3 independent experiments. *, 
P<0.05 versus control.  
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Figure 7. Sp1 binds to the promoter region of HMGR and its insulin-induced 
increased affinity is prevented by DON. 3T3-L1 adipocytes were pretreated 
with or without 20 µM DON for 16 h. After 4 h of pretreatment, cells were treated 
with or without 500 pM insulin for 12 h. Following treatments, DNA was sonicated 
and chromatin immunoprecipitation was performed using an Sp1 antibody. 
Purified DNA and primers specific to the Sp1 binding site in the promoter region 
of HMGR were utilized for qPCR analyses. Ct values from qPCR were 
normalized to the background IgG antibody using the fold enrichment method. 
Means values ± SEM are shown from 3 independent experiments. *, P<0.05 
versus control.  
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Figure 8. Hyperinsulinemia Promotes and DON Protects Against 
Transcriptional Activation of the HMGR Promoter. 3T3-L1 adipocytes were 
electroporated with the proximal promoter sequence (-284 to +36) of the HMGR 
promoter cloned into pGL2B luciferase reporter plasmids (A). This promoter 
sequence contained 3 consensus sequences for Sp1 binding (B). After a 16-18 h 
recovery period, cells were pretreated with or without 20 µM DON for 16 h. After 
4 h of pretreatment, cells were treated with or without 500 pM insulin for 12 h. 
Following treatments, luciferase activity was measured and normalized relative to 
Renilla (C). Means values ± SEM are shown from 3 independent experiments. *, 
P<0.05 versus control.  
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glycosylation of Sp1 results in increased binding and activation of these genes, in 
turn, promoting an increase in cholesterol synthesis and PM cholesterol content.  
 
Inhibition of the HBP Ablates the Cholesterolgenic Response: It was 
next determined whether DON could protect against the increases in 
mRNA/protein content of HMGR observed with hyperinsulinemia. HMGR mRNA 
obtained from cells treated with 500 pM insulin displayed a characteristic 4 fold 
increase in mRNA compared to control cells (Fig. 9A). Treatment with DON 
completely abrogated the insulin-induced increase in HMGR mRNA. 
Interestingly, in control cells there was a slight, but significant lessening of the 
mRNA levels of HMGR. The reduction observed was approximately 40% 
compared to control cells. In addition to measuring mRNA, the effect of DON on 
the protein content of HMGR was also assessed. While hyperinsulinemia 
promoted a 55% increase in protein levels of HMGR (Fig. 9B), DON protected 
against this alteration. In contrast to that observed with the mRNA data, the 
decrease in mRNA levels of HMGR witnessed in control cells did not amount to a 
detectable loss in total protein content. 
 
Sp1 Inhibition Protects Against Hyperinsulinemia-induced Glucose 
Transport Dysfunction: Taken together, this data suggested that 
hyperinsulinemia, through engaging the HBP, could promote an increase in 
cholesterol synthesis through alterations in the glycosylation status of Sp1. Study 
thus next sought to decipher the precise role of Sp1 in mediating these 
transcriptional alterations. As such, a specific inhibitor of Sp1 binding to GC box
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Figure 9. Inhibition of the HBP pathway protects against the 
cholesterolgenic response. 3T3-L1 adipocytes were pretreated with or without 
20 µM DON for 16 h. After 4 h of pretreatment, cells were treated with or without 
500 pM insulin for 12 h. Following treatments, the mRNA content of Hmgcr (A) 
was determined and normalized to 36B4. Means values ± SEM are shown from 
3-8 independent experiments. *, P<0.05 versus control. Protein levels of HMGR 
(B) were also determined by immunoblotting, normalized to actin. Means values 
± SEM are shown from 5 independent experiments. *, P<0.05 versus control.  
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regions in the DNA, mithramycin, was employed (337). Protein levels of HMGR 
were elevated in cells treated with hyperinsulinemia, but corrected in cells treated 
in the presence of mithramycin (Fig. 10A). In addition, PM cholesterol content 
was increased by approximately 35% under hyperinsulinemic conditions. This 
increase, however, was protected against when cells were cotreated with 
mithramycin (Fig. 10B). To next assess if mithramycin could correct against a 
loss in F-actin previously observed in cells cultured in hyperinsulinemic 
conditions, confocal microscopy was employed. In cells treated with 
hyperinsulinemia, there was a marked qualitative loss in F-actin staining as 
assessed with a phalloidin compared to control cells (Fig. 11A). This apparent 
loss in staining was corrected in cells treated with hyperinsulinemia in the 
presence of mithramycin. Quantification of the actin staining using MetaMorph 
software, normalized to Syto 60, a nuclear stain, revealed a 55% loss in F-actin 
that was corrected with mithramycin treatment (Fig. 11B). Finally, it was 
determined whether mithramycin treatment, through correcting these 
membrane/cytoskeletal derangements, could protect against an impairment in 
insulin responsiveness induced by hyperinsulinemia. Glucose uptakes revealed 
that hyperinsulinemia impaired the acute ability of insulin to stimulate glucose 
uptake by approximately 50% compared to control cells (Fig. 12). In contrast, 
insulin-stimulated glucose uptake was not impaired by mithramycin treatment of 
control cells. Rather, mithramycin restored insulin responsiveness in cells treated 
with hyperinsulinemia.  
In summary, data from these in vitro studies presented in Chapter IIA offer 
several novel observations. First, accompanying the hyperinsulinemia-induced
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Figure 10. Inhibition of Sp1 binding activity protects against cholesterol 
accrual. 3T3-L1 adipocytes were pretreated with or without 100 nM mithramycin 
(MTR) for 16 h. After 4 h of pretreatment, cells were treated with or without 500 
pM insulin for 12 h. Following treatments, the protein levels of HMGR (A) were 
determined by immunoblotting, normalized to actin. Means values ± SEM are 
shown from 4 independent experiments. *, P<0.05 versus control. PM cholesterol 
content (B) was also assessed and normalized to total PM protein content. Mean 
values ± SEM are shown from 5 independent experiments. *, P<0.05 versus 
control.  
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Figure 11. Inhibition of Sp1 binding activity protects against F-actin loss.  
3T3-L1 adipocytes were pretreated with or without 100 nM mithramycin (MTR) 
for 16 h. After 4 h of pretreatment, cells were treated with or without 500 pM 
insulin for 12 h. Following treatments, cells were fixed and subjected to 
immunofluorescence microscopy with phalloidin for F-actin imaging and a Syto 
60 nucleic stain (A). All microscope settings were identical between groups. 
Quantification of signal intensity from X60 magnification fields was performed 
using MetaMorph software normalizing actin intensity over a 30-mm area to Syto 
60 staining (B). Means values ± SEM are shown from 3 independent experiments 
with 4-6 images collected per experiment. *, P<0.05 versus control.  
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Figure 12. Inhibition of Sp1 binding activity protects against glucose 
transport dysfunction. 3T3-L1 adipocytes were pretreated with or without 100 
nM mithramycin (MTR) for 16 h. After 4 h of pretreatment, cells were treated with 
or without 500 pM insulin for 12 h. Following treatments, cells were placed in 
serum free media for 1 h. During the last 30 min, cells were incubated with 100 
nM insulin to stimulate glucose uptake. Means values ± SEM are shown from 5 
independent experiments. *, P<0.05 versus unstimulated control. #, P<0.05 
versus stimulated control. 
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activation of the HBP previously shown (7), activation of this pathway promotes 
an increase in O-GlcNAc on Sp1 (Fig. 13). Second, this increase in O-GlcNAc 
promotes an increase in the binding affinity of this transcription factor toward the 
promoter regions of cholesterolgenic genes. Third, we provide evidence that the 
HBP plays a direct role in the activation of the promoter region of HMGR as 
hyperinsulinemia promoted and HBP inhibition protected against increases in 
luciferase reporter activity. Fourth, it was found that O-GlcNAc of Sp1 may play a 
crucial role in the activation of a cholesterolgenic program that promotes insulin 
resistance. Inhibition of Sp1 with mithramycin resulted in a restoration of protein 
levels of HMGR. Concurrently, mithramycin treatment also protected against PM 
cholesterol accrual, F-actin loss, and impaired glucose transport induced by 
hyperinsulinemia. In continuation of these studies, we next aimed to determine 
the role of the micronutrient chromium in attenuating glucose flux through this 
pathway. Of particular interest is whether an effect of chromium on this pathway 
could serve as a basis of its action in benefiting glucose and lipid metabolism.  
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Figure 13. Model of hyperinsulinemia-induced insulin resistance in 
adipocytes. Exposure of 3T3-L1 adipocytes to hyperinsulinemia induces insulin 
resistance. Specifically, exposure to hyperinsulinemia promotes an increase in 
O-GlcNAc on Sp1, leading to its increased binding to the promoter regions of the 
genes Srebf1 and Hmgcr. Increases in the protein product SREBP1 can 
positively feedback resulting in activation of its own promoter as well as the 
promoter of HMGR. This could also occur through the saturation of Insig2, 
leading to increased processing of SREBP1. The resulting increases in HMGR 
promote an accumulation of PM cholesterol, disruption of F-actin structure, and 
impairment in glucose transport (IGT). Treatment with the HBP inhibitor DON or 
the Sp1 binding inhibitor mithramycin (not shown) protects against PM 
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cholesterol accumulation and defects in insulin responsiveness. Other 
transcription factors, such as LXR, are known to be targets of the HBP and may 
combinatorially promote the activation of genes involved in regulating cholesterol 
synthesis, thereby impairing glucose transport.  
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II.B.  Chromium Improves Cellular Cholesterol Efflux, ABCA1 
Functionality, and Rab8 Cycling Rendered Defective by Hyperinsulinemia 
in Adipocytes  
 
II.B.1. Summary 
Studies presented in the previous chapter suggested a novel mechanism by 
which hyperinsulinemia could promote alterations in cellular cholesterol 
homeostasis through engaging the HBP. A puzzling observation, however, 
presented itself in that previous in vivo analyses validated elevations in 
membrane content associated with insulin resistance (11, 338). This finding was 
paradoxical in light of the fact that the RCT should protect against increases in 
PM cholesterol content through efflux processes. This would result in the 
elimination of excess cholesterol to a growing HDL particle, which would then be 
transported to the liver for secretion in the bile. Given this observation, the 
studies presented in this chapter sought to discern the mechanisms whereby 
insulin resistance, induced by hyperinsulinemia, could promote alterations in 
cholesterol efflux in 3T3-L1 adipocytes. Concurrently, these studies sought to 
elucidate a mechanistic understanding for the role of chromium in promoting 
optimal lipid metabolism. The generation of the rate-limiting HDL sub-particle, 
pre-β-1, was found to be impaired in adipocytes exposed to hyperinsulinemia and 
corrected with concurrent culturing in CrPic. Mechanistically, it was found that 
endosomal cholesterol content was elevated by hyperinsulinemia and reversed 
with CrPic. This increase and restoration of endosomal cholesterol levels was 
associated with an impairment and correction of ABCA1 trafficking to the PM, 
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respectively. Furthermore, it was found that the cycling of Rab8, known to be 
found on the same vesicles as ABCA1, was impaired with hyperinsulinemia and 
corrected with CrPic treatment. Finally, it was observed that inhibition of the HBP 
or direct activation of AMPK mimicked the effects of CrPic on improving these 
parameters and cholesterol efflux processes. Taken together, this data suggests 
an unappreciated basis for the coexistence of low HDL and metabolic 
derangements such as hyperinsulinemia. This data also places increased HBP 
activity as a potential mediator of defects in both glucose and cholesterol 
metabolism.  
 
II.B.2. Results 
 
Hyperinsulinemia Impairs ApoA-I-mediated Cholesterol Efflux in 
Adipocytes: Previous studies conducted in humans with similar levels of total 
HDL showed marked differences in the ability of macrophages to efflux 
cholesterol, a cardioprotective event. In delineating the cause, it was determined 
that the ability of macrophages to efflux cholesterol in serum with similar levels of 
HDL correlated with the concentration of pre-β-1 HDL in the serum (339). While 
several tissues contribute to this sub-fraction, recent evidence seeking to define 
the relationship between insulin resistance and low HDL has suggested that the 
expanding pool of cholesterol found in adipose tissue may play an important role 
in these processes in vivo (201, 340). As such, studies first attempted to discern 
the effects of hyperinsulinemia on the generation of pre-β-1 HDL. Treatment of 
3T3-L1 adipocytes with hyperinsulinemia (5 nM, 12 h) resulted in an 
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approximately 30% impairment in the ability of these cells to efflux cholesterol 
compared to control cells (Fig. 14). Strikingly, treatment with CrPic prevented 
against the impairment in cholesterol efflux induced by hyperinsulinemia. To 
determine if the alterations in cholesterol efflux resulted from a loss in the protein 
content of ABCA1, total levels were examined in these conditions. Interestingly, 
total levels of ABCA1 were found to be unchanged, yet trended (P=0.20) toward 
being increased in cells cultured with hyperinsulinemia, suggesting a loss of total 
ABCA1 could not account for the impaired efflux (Fig. 15A). It was thus next 
examined if perhaps the trafficking of ABCA1 to the PM was affected by 
hyperinsulinemia. Treatment with hyperinsulinemia was found to provoke an 
approximate 40% loss in the amount of ABCA1 present at the PM (Fig. 15B). 
CrPic treatment restored PM ABCA1 to levels witnessed in control cells. 
Reciprocally, an almost 3 fold increase in endosomal ABCA1 was detected in 
cells treated with hyperinsulinemia (Fig. 15C). This increase in endosomal 
ABCA1 was normalized upon treatment with CrPic. Together this suggested a 
defect in delivery of ABCA1 to the PM as a basis for the impaired cholesterol 
efflux.  
 
Hyperinsulinemia Impairs the Functional Cycling of Rab8: Recent 
findings have established that the small G-protein Rab8 serves as a key protein 
in the regulatory machinery leading to the redistribution of ABCA1 to the PM to 
facilitate the removal of cholesterol (218, 219). Furthermore, it has been shown       
that in conditions such as NPC, alterations in cholesterol content can sequester 
Rab proteins on endosomal membranes, thereby keeping them in an inactive
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Figure 14. Hyperinsulinemia impairs cholesterol efflux in adipocytes. 3T3-
L1 adipocytes were labeled with 0.5 µCi/ml 3H-cholesterol for 24 h. Cells were 
then washed and pretreated with or without 1 µM CrPic for 16 h. After 4 h of 
pretreatment, cells were treated with or without 5 nM insulin for 12 h. Following 
treatments, cells were placed in media containing 0.2% BSA and 10 µg/ml lipid-
free ApoA1 for 4 hours. 3H-cholesterol was then measured in the medium and 
the cells by using a scintillation counter. The percentage of acceptor-specific 
efflux was calculated using the equation: medium/(medium+cells). Values 
obtained in the absence of acceptor were subtracted to account for non-specific 
3H-cholesterol efflux/leakage. Means values ± SEM are shown from 3-10 
independent experiments. *, P<0.05 control. 
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Figure 15. Hyperinsulinemia impairs ABCA1 trafficking to the PM. 3T3-L1 
adipocytes were pretreated with or without 1 µM CrPic for 16 h. After 4 h of 
pretreatment, cells were treated with or without 5 nM insulin for 12 h. Following 
treatments, whole cell lysates were prepared and protein levels of ABCA1 were 
determined by immunoblotting (A), normalized to actin. Mean values ± SEM are 
shown from 3-4 independent experiments. PM fractions were prepared and 
ABCA1 protein levels were determined by immunoblotting (B), normalized to 
Ponceau. Mean values ± SEM are shown from 4-8 independent experiments. *, 
P<0.05 control. Endosomal membrane (EM) fractions were prepared and ABCA1 
protein levels were determined by immunoblotting (C), normalized to Ponceau. 
Mean values ± SEM are shown from 4-7 independent experiments. *, P<0.05 
control. 
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form on membranes and preventing their cycling to the cytosol to allow for 
dynamic and continued trafficking (341). As such, it was next examined whether 
the disrupted delivery of ABCA1 to the PM could be due to alterations in the 
functional cycling of Rab8. Similar to ABCA1, Rab8 was increased by 
approximately 50% in endosomal fractions of cells treated with hyperinsulinemia 
(Fig. 16A). This increase was prevented in cells that were concurrently treated 
with CrPic. Concomitant with this increase in endosomal Rab8 content was a 
diminished level of Rab8 found in cytosolic fractions obtained from cells treated 
with hyperinsulinemia (Fig. 16B). Treatment with CrPic in the presence of 
hyperinsulinemia prevented this approximately 30% loss in cytosolic Rab8 
content. Taken together, this data suggested that the loss in ABCA1 delivery to 
the PM could be the consequence of alterations in the appropriate cycling of this 
protein.  
 
Hyperinsulinemia Promotes and AMPK Activation Attenuates Increased 
Endosomal Cholesterol Content: To determine if increased endosomal 
cholesterol content could be mediating the dysfunctional ABCA1 trafficking and 
Rab8 cycling, this parameter was next examined. Cholesterol analyses revealed 
a substantial increase in endosomal cholesterol content in cells cultivated under 
hyperinsulinemic conditions (Fig. 17A). This increase in cholesterol content was 
corrected upon treatment with CrPic. Interestingly, recent evidence suggests that 
AMPK might be a target of chromium action, suggesting a potential mechanism 
for the beneficial effect of CrPic treatment on endosomal cholesterol (281). As 
such, it was next examined if CrPic resulted in an activation of AMPK in these
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Figure 16. Hyperinsulinemia impairs the functional cycling of Rab8. 3T3-L1 
adipocytes were pretreated with or without 1 µM CrPic for 16 h. After 4 h of 
pretreatment, cells were treated with or without 5 nM insulin for 12 h. Following 
treatments, endosomal membrane (EM) fractions were prepared and protein 
levels of Rab8 were determined by immunoblotting (A), normalized to Ponceau. 
Mean values ± SEM are shown from 5-13 independent experiments. *, P<0.05 
control. Cytosolic fractions were also prepared and protein levels of Rab8 were 
determined by immunoblotting (B), normalized to Ponceau. Mean values ± SEM 
are shown from 5-13 independent experiments. *, P<0.05 control.  
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cells. These studies revealed that treatment with CrPic resulted in an activation 
of AMPK in both control and hyperinsulinemic cells (Fig. 17B). In addition, the 
activation observed was found to be similar to that induced by the AMPK 
activator, 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboximide (AICAR). In fact, 
AICAR was also found to restore endosomal membrane cholesterol content to 
levels observed in control cells (Fig. 17C). This treatment was also found to 
correct the dysfunctional ABCA1 trafficking and Rab8 cycling induced by 
hyperinsulinemia.  
 
Inhibition of the HBP or Activation of AMPK Restores Cholesterol 
Efflux: In contrast to AMPK, increases in HBP flux have been shown in the 
previous section to provoke cholesterol accrual induced by hyperinsulinemia. The 
effect of HBP inhibition and activation of AMPK by AICAR on cholesterol efflux 
was next examined. These studies revealed that DON and AICAR had similar 
effects as CrPic with regard to preventing the impairment in cholesterol efflux 
induced by hyperinsulinemia (Fig. 18). Neither agent, nor CrPic, displayed any 
effects on efflux processes in control cells. In addition, the cholesterol lowering 
agent, methyl-β-cyclodextrin, was also observed to correct against defective 
cholesterol efflux.  
In summary, data from these in vitro studies presented in Chapter IIB offer 
several novel observations. First, they add growing support for the role of 
adipocytes in cholesterol efflux with data suggesting that this process becomes 
impaired by pathophysiological hyperinsulinemia. Second, they suggest that 
hyperinsulinemia-induced cholesterol accrual is not simply the result of ectopic
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Figure 17. Hyperinsulinemia-induced endosomal cholesterol accrual is 
mitigated with CrPic or AICAR. 3T3-L1 adipocytes were pretreated with or 
without 1 µM CrPic for 16 h. After 4 h of pretreatment, cells were treated with or 
without 5 nM insulin for 12 h. AICAR treatments were performed after the 12 h 
insulin exposure for 45 min. Following treatments, endosomal membrane (EM) 
fractions were prepared and cholesterol content was measured (A and C) 
normalized to total endosomal protein content. Mean values ± SEM are shown 
from 3-8 independent experiments. *, P<0.05 control. Following treatments, 
whole cell lysates were also prepared and phosphorylation of AMPK was 
determined by immunoblotting (B), normalized to total levels of AMPK. Mean 
values ± SEM are shown from 6 independent experiments. *, P<0.05 control.  
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Figure 18. AMPK activation and HBP inhibition protect against 
hyperinsulinemia-induced impairments in cholesterol efflux. 3T3-L1 
adipocytes were labeled with 0.5 µCi/ml 3H-cholesterol for 24 h. Cells were then 
washed and pretreated with or without 1 µM CrPic or 20 µM DON for 16 h. After 
4 h of pretreatment, cells were treated with or without 5 nM insulin for 12 h. 
AICAR treatments were performed after the 12 h insulin exposure for 45 min. 
Following treatments, cells were placed in media containing 0.2% BSA and 10 
µg/ml lipid-free ApoA1 for 4 hours. 3H-cholesterol was then measured in the 
medium and the cells by using a scintillation counter. The percentage of 
acceptor-specific efflux was calculated using the equation: 
medium/(medium+cells). Values obtained in the absence of acceptor were 
subtracted to account for non-specific 3H-cholesterol efflux/leakage. Means 
values ± SEM are shown from 3-10 independent experiments. *, P<0.05 control. 
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cholesterol at the PM as endosomal cholesterol content was also found to be 
elevated. Third, these data support a mechanism by which endosomal 
cholesterol accumulation induced by hyperinsulinemia could stabilize Rab8 on 
these membranes, thereby interfering with the necessary cycling of this protein 
for optimal delivery of ABCA1 to the PM (Fig. 19). These data also suggest that 
activation of AMPK by CrPic or AICAR could improve cholesterol efflux 
processes by inhibiting cholesterol synthesis and accrual in the endosomal 
membranes. Further, inhibition of the HBP mimicked these beneficial effects, 
suggesting a role of this pathway in promoting derangements in lipoprotein 
metabolism in addition to glucose homeostasis. Of particular interest for future 
studies was to determine if CrPic treatment, perhaps through activation of AMPK, 
could impinge upon the HBP pathway to exert beneficial effects on glucose 
metabolism in adipose tissue and skeletal muscle.  
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Figure 19. Model of hyperinsulinemia-induced impairment in cholesterol 
efflux. Under healthy conditions, 3T3-L1 adipocytes respond to cell signaling 
processes to promote removal of excess cholesterol or phospholipids to lipid 
poor ApoA-I. This process is mediated by Rab8, which delivers ABCA1 to the 
PM, is extracted by GDI, and is redelivered to endosomal pools to promote 
dynamic trafficking of ABCA1 to the PM. In adipocytes, chronic exposure to 
hyperinsulinemia results in the activation of the HBP, promoting excess PM and 
EM cholesterol content. These increases in EM cholesterol content may perturb 
the ability of Rab8 to be extracted by GDI, thereby sequestering it in endosomal 
pools and inhibiting the proper delivery of ABCA1 to the PM. Treatment of 
adipocytes with chromium resulted in the activation of AMPK. This increase in 
AMPK activity was associated with a prevention of hyperinsulinemia-induced EM 
cholesterol accrual as well as dysfunctional trafficking of ABC1 to the PM. AMPK 
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stimulation by AICAR (not shown) also promoted the appropriated cycling and 
trafficking of Rab8 and ABCA1, respectively, correcting impaired cholesterol 
efflux. Additionally, direct inhibition of the HBP was found to protect against these 
derangements and restore cholesterol efflux.  
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II.C. Chromium Protects Against Hexosamine-Induced Cholesterol 
Accumulation and Insulin Resistance 
 
II.C.1.  Summary 
Studies presented in the previous chapters suggested a novel mechanism by 
which hyperinsulinemia could engage the HBP, potentially promoting alterations 
in both PM and EM cholesterol content. Direct inhibition of the HBP prevented 
glucose transport dysfunction as well as perturbed trafficking of ABCA1 to the 
PM. In addition, it was observed that chromium had similar effects as HBP 
inhibition with regard to cholesterol efflux studies. Given the numerous studies 
demonstrating a beneficial effect of chromium supplementation on at least one 
parameter of glucose metabolism in humans (23, 233, 234, 236-238, 240), we 
sought to determine if chromium could impinge on the HBP, thereby promoting 
an attenuation in PM cholesterol accrual and impaired glucose uptake. In 
adipocytes treated with hyperinsulinemia, a characteristic increase in the 
protein/mRNA levels of HMGR was observed. Additionally, increases in the O-
GlcNAc status of Sp1 were found under these conditions, associated with similar 
gains in promoter affinity and activity with regard to HMGR. This was associated 
with an impairment in insulin action despite intact insulin signaling to AS160. 
Strikingly, CrPic resulted in an attenuation of HBP pathway activity as assessed 
by glycosylation of Sp1. In congruence with the effect of glycosylation in 
promoting an increased affinity to HMGR, CrPic resulted in a reduction in the 
affinity to the HMGR promoter as well as promoter activity as assessed by ChIP 
and luciferase assays. While hyperinsulinemia promoted an impairment in insulin 
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responsiveness, concurrent treatment with CrPic prevented this effect. CrPic 
treatment did not amplify insulin signaling to mediate the improved 
responsiveness. In vivo validations studies were performed in C57Bl/6J mice 
placed on an 8 week low-/high-fat diet with or without CrPic supplementation. 
Mice fed a high-fat diet displayed glucose intolerance and increased circulating 
plasma insulin compared to low-fat fed littermates. In addition, epididymal fat 
pads taken from these mice displayed increases in cholesterolgenic processes 
and membrane cholesterol content. In high-fat animals supplemented with CrPic 
these cellular derangements were prevented and insulin sensitivity was markedly 
improved.  
 
II.C.2. Results 
 
CrPic Protects Against Hyperinsulinemia-induced PM Cholesterol 
Accrual: Results presented in the previous chapter demonstrate that 
pathophysiologic hyperinsulinemia promotes increases in PM cholesterol 
content, in turn perturbing the cortical F-actin structure necessary for proper 
GLUT4 translocation. Ex vivo examination of skeletal muscle tissues from insulin-
resistant Zucker rats demonstrated that correction of membrane cholesterol 
restores F-actin structure and insulin sensitivity (338). Studies first evaluated 
whether CrPic treatment could protect against hyperinsulinemia-induced PM 
cholesterol accrual. PM cholesterol content was elevated by approximately 50% 
the gain in membrane cholesterol content observed with hyperinsulinemia. No 
alterations in cholesterol content were observed in control cells treated with 
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CrPic. To determine if CrPic treatment was correcting cholesterol content through 
an inhibition of synthesis, total levels of HMGR were analyzed. Under 
hyperinsulinemic conditions, HMGR was found to be increased by 60% (Fig. 
20B). CrPic treatment inhibited this effect. To next determine if the alterations in 
the protein levels of HMGR were the result of alterations in transcription, mRNA 
levels of HMGR were assessed. These analyses revealed that hyperinsulinemia 
promoted an approximate 5 fold increase in the mRNA expression of HMGR that 
CrPic corrected (Fig. 20C). No effect of CrPic treatment on HMGR protein or 
mRNA content was observed in control cells.  
 
CrPic Reduces HBP-induced O-GlcNAc Modification of Sp1: Work 
presented in the previous chapters linked excessive glucose flux through the 
HBP in provoking a cholesterolgenic response through the activation of Sp1 by 
O-GlcNAc. To test where or not CrPic could inhibit the increased HMGR mRNA/ 
protein through altering glucose flux through the HBP and subsequent 
modification of Sp1, immunoprecipitation was performed. These analyses 
revealed an approximate 55% increase in the O-GlcNAc modification of Sp1 
induced by hyperinsulinemia (Fig. 21). While CrPic treatment did not affect this 
parameter in control cells, treatment blunted the effects of hyperinsulinemia in 
engaging this pathway. Together, these results suggested inhibition of HBP-
induced cholesterol synthesis as a potential mechanism for CrPic action to 
improve insulin responsiveness.  
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Figure 20. CrPic protects against hyperinsulinemia-induced cholesterol 
synthesis. 3T3-L1 adipocytes were pretreated with or without 10 nM CrPic for 16 
h. After 4 h of pretreatment, cells were treated with or without 5 nM insulin for 12 
h. Following treatments, PM cholesterol content (A) was assessed and 
normalized to total PM protein content. Mean values ± SEM are shown from 5 
independent experiments. *, P<0.05 versus control. Protein levels of HMGR (B) 
were determined by immunoblotting, normalized to actin. Mean values ± SEM 
are shown from 4 independent experiments. *, P<0.05 versus control. The mRNA 
content of Hmgcr (C) was also determined and normalized to 36B4. Means 
values ± SEM are shown from 5 independent experiments. *, P<0.05 versus 
control. 
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Figure 21. Hyperinsulinemia provokes and CrPic inhibits O-linked 
glycosylation of Sp1. 3T3-L1 adipocytes were pretreated with or without 10 nM 
CrPic for 16 h. After 4 h of pretreatment, cells were treated with or without 500 
pM insulin for 12 h. Following treatments, lysates were prepared and 
immunoprecipitated with an Sp1 antibody. Eluted samples were then 
immunobloted with an RL2 antibody to detect O-linked glycosylation of Sp1. The 
glycosylation of Sp1 was normalized to an input sample of Sp1 from lysed 
samples. Means values ± SEM are shown from 5-6 independent experiments. *, 
P<0.05 versus control.  
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Hyperinsulinemia Augments and CrPic Attenuates Sp1 Promoter 
Affinity: Study next sought to determine if CrPic treatment, potentially through 
reducing O-GlcNAc modification of Sp1, could alter its binding affinity toward the 
promoter region of HMGR. This could be mediated through direct targeting of 
Sp1 toward the promoter region or alternatively, through preventing the 
degradation of this protein as study has previously demonstrated (134, 202). To 
further examine this process, ChIP was performed. Hyperinsulinemic culturing 
conditions resulted in a characteristic increase in the association of Sp1 toward 
the promoter (Fig. 22), whereas concurrent treatment with CrPic markedly 
attenuated this association.  
  
CrPic Protects against Hyperinsulinemia-induced Activation of the 
HMGR Promoter: Study next sought to delineate the effects of CrPic treatment 
on the transcriptional activity of the HMGR promoter. Plasmids containing the 
coding sequence (-284 to +36) of the promoter, containing 3 Sp1 binding 
moieties, were electroporated into adipocytes. Further in silico analyses 
conducted using MatInspector demonstrated the consensus binding sites for Sp1 
as well as other transcription factors involved in the activation of HMGR (Fig. 
23A). Next, luciferase assays were performed to examine how CrPic treatment 
affected the promoter activity. In cells exposed to hyperinsulinemia, a 2 fold 
increase in the promoter activity was observed (Fig. 23B). Consistent with CrPic 
inhibiting this response through reducing the affinity of Sp1 to the promoter, this
treatment blunted the increase in activity observed with hyperinsulinemia. Of 
note, CrPic did not have any effect on the luciferase activity in control cells.  
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Figure 22. CrPic reduces hyperinsulinemia-induced association of Sp1 
toward the HMGR promoter. 3T3-L1 adipocytes were pretreated with or without 
10 nM CrPic for 16 h. After 4 h of pretreatment, cells were treated with or without 
500 pM insulin for 12 h. Following treatments, DNA was sonicated and chromatin 
immunoprecipitation was performed using an Sp1 antibody. Purified DNA and 
primers specific to the Sp1 binding site in the promoter region of HMGR were 
utilized for qPCR analyses. Ct values from qPCR were normalized using the 
percent input method. Means values ± SEM are shown from 3 independent 
experiments. *, P<0.05 versus control.  
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Figure 23. Hyperinsulinemia activates and CrPic reduces promoter activity 
of HMGR. 3T3-L1 adipocytes were electroporated with the minimal promoter 
sequence (-284 to +36) of HMGR cloned into pGL2B luciferase reporter plasmids 
(A). The location of various sequence motifs that serve as sites of recognition for 
transcription factors are underlined. The +1 indicates the start site of transcription 
and the asterisk indicates the start site of translation. After a 16-18 h recovery 
period, cells were pretreated with or without 10 nM CrPic for 16 h. After 4 h of 
pretreatment, cells were treated with or without 500 pM insulin for 12 h. Following 
treatments, luciferase activity was measured (B) and normalized relative to 
Renilla. Means values ± SEM are shown from 3 independent experiments. *, 
P<0.05 versus control.  
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CrPic Protects against Impaired Glucose Transport: With data 
suggesting that CrPic could protect against hyperinsulinemia-induced defects in 
insulin responsiveness through attenuation of cholesterol synthesis, glucose 
uptakes were next performed. Insulin-stimulated glucose transport was found to 
be reduced by approximately 55% with hyperinsulinemia (Fig. 24). CrPic 
treatment completely ameliorated the glucose transport dysfunction induced by 
hyperinsulinemia. Studies have suggested a beneficial mechanism of CrPic 
action on glucose transport might entail countering defects in insulin signaling 
observed in animal models of insulin resistance (342-345). Yet other lines of 
evidence suggest that pathophysiologic hyperinsulinemia (5 nM) does not impair 
insulin signaling (8, 12). It was thus next characterized whether the 500 pM dose 
of insulin induced a defect in insulin signaling and, if so, whether CrPic treatment 
could counter this effect. Hyperinsulinemia, however, was not found to alter 
insulin-stimulated phosphorylation of Akt2 at Ser 474 (Fig. 25A), nor did it affect 
the phosphorylation of its downstream substrate, AS160 (Fig. 25B). Similarly, 
CrPic treatment had no effect on insulin signaling in control cells, nor did it have 
a beneficial action in cells co-treated with hyperinsulinemia. 
 
In Vivo CrPic Supplementation Study Design: Taken together, these in 
vitro findings suggested that CrPic may benefit glucose metabolism by inhibiting 
HBP activity thereby attenuating cholesterol synthesis. To begin to translate 
these findings, study utilized the obesity-prone C57Bl/6J mice placed on a LF or 
HF diet over a period of 8 weeks. The development of obesity and insulin 
resistance as a result of excessive intake of dietary fat has been established in
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Figure 24. CrPic attenuated glucose transport dysfunction induced by 
hyperinsulinemia. 3T3-L1 adipocytes were pretreated with or without 10 nM 
CrPic for 16 h. After 4 h of pretreatment, cells were treated with or without 500 
pM insulin for 12 h. Following treatments, cells were placed in serum free media 
for 1 h. During the last 30 min, cells were incubated with 100 nM insulin to 
stimulate glucose uptake. Means values ± SEM are shown from 5 independent 
experiments. *, P<0.05 versus unstimulated control. #, P<0.05 versus stimulated 
control. 
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Figure 25. CrPic did not enhance nor did hyperinsulinemia impair insulin 
signaling. 3T3-L1 adipocytes were pretreated with or without 10 nM CrPic for 16 
h. After 4 h of pretreatment, cells were treated with or without 500 pM insulin for 
12 h. Following treatments, cells were placed in serum free media for 1 h. During 
the last 5 min, cells were incubated with 100 nM insulin to induce 
phosphorylation of insulin signaling proteins. Phosphorylation of Akt (A) was 
determined by immunoblotting, normalized to total Akt. Means values ± SEM are 
shown from 4 independent experiments. *, P<0.05 versus respective 
unstimulated treatment. Phosphorylation of AS160 (B) was also determined by 
immunoblotting, normalized to total AS160. Means values ± SEM are shown from 
4 independent experiments *, P<0.05 versus respective unstimulated treatment.  
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these animals by several studies (346-351), For these studies, chromium 
supplementation was dissolved in the drinking water at a dose of 8 µg/kg body 
weight per day, which given an average human body mass of 75 kg, represents a 
clinically efficacious dose of 600 µg. The mice in these studies were fed ad 
libitum a NIH standard chow diet for two weeks and then subsequently placed on 
a modified LF diet containing palm oil instead of lard to better mimic the fatty acid 
composition of western societies (352). After a three week acclimation period, 
mice were divided into one of four groups (Fig. 26). LF fed mice were given 20% 
kcal from protein, 70% kcal from carbohydrates, and 10% kcal from fat. In 
contrast, the HF diet consisted of 20% kcal from protein, 35% kcal from 
carbohydrates and 45% kcal from fat. In addition, the diets were made with a 
chromium free mineral mix (S17902) and Avicel PH101 (instead of cellulose, 
which contains chromium). Chromium potassium sulfate was then added back to 
the diets to provide a 380 µg, which given a 0.5% absorption, represents 
approximately 2 µg in the bloodstream. Body weight was measured once per 
week throughout the course of the study and was found to be significantly 
elevated by HF feeding (Fig. 27). While chromium supplementation has garnered 
popularity by the belief that it can mitigate weight gain, study has demonstrated 
that doses up to 1000 µg do not independently influence body weight (353, 354). 
In congruence with these data, CrPic did not affect weight gain in mice fed a HF 
diet. Importantly, the observed changes in body weight were independent of 
changes in food consumption at any point in the study (Fig. 28A). Additionally, 
water consumption was measured once per week throughout the study,
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Figure 26. Study design for diet intervention and CrPic supplementation. 
C57Bl/6J mice 4 weeks of age were acclimated with or without CrPic 
supplementation in their drinking water. Mice were fed ad libitum NIH standard 
chow for a period of 2 weeks. After this time, mice were placed on the modified 
LF diet for 3 additional weeks. At time 0, mice were then placed on either a LF or 
HF diet with or without CrPic supplementation for a period of 8 weeks. All 
procedures and ex vivo tissue analyses were performed at the completion of this 
dietary intervention.  
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Figure 27. HF feeding regardless of chromium status increases body 
weight. C57Bl/6J mice were initially acclimated on a LF diet in the presence 
(blue) or absence (black) of chromium in their drinking water. At 0 weeks, mice 
were then separated again into LF (triangle) or HF (circle) groups ± continued 
supplementation with chromium. Body weight was measured once per week 
throughout the duration of the study. Means values ± SEM are shown from 12 
mice per group. *, P<0.05 versus LF. **, P<0.01 versus LF. ***, P<0.001 versus 
LF.  
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averaging 2.6-2.7 ml/day (Fig. 28B). Careful monitoring of this intake was 
necessary to ensure appropriate CrPic supplementation.  
 
CrPic Improves Glucose and Insulin Tolerance in Mice Fed a HF Diet: 
To characterize the effect of HF feeding and CrPic supplementation on whole 
body glucose tolerance and insulin sensitivity, intraperitoneal glucose and insulin 
tolerance tests (IPGTT and IPITT) were performed on C57Bl/6J mice following 
dietary intervention. For these analyses, mice were fasted for 6 hours prior to 
testing, as previous study has demonstrated this fasting interval is best for 
assessing glucose tolerance (355). In the glucose tolerance testing, mice were 
injected with 2 g D-glucose/kg body weight and for IPITT mice were injected with 
1.0 unit of insulin/kg body weight. Mice fed a HF diet had a marked impairment in 
glucose tolerance compared to LF fed mice (Fig. 29A). Mice fed a HF diet 
supplemented with CrPic had an improvement in glucose tolerance. Area under 
the curve for the glucose tolerance test also demonstrated an impairment with 
HF feeding and an improvement with CrPic supplementation (Fig. 29B). To 
supplement the glucose tolerance data, insulin tolerance testing was performed 
in these mice after 8 weeks of HF feeding. In LF fed mice, insulin promoted a 
rapid reduction in plasma glucose (Fig. 30A). In contrast, the ability of insulin to 
lower plasma glucose levels over the course of the study was reduced in HF fed 
mice, while CrPic supplementation improved insulin sensitivity. The area above 
the curve for the insulin tolerance test further evinced this alteration in insulin
sensitivity (Fig. 30B). As a final measure of insulin sensitivity, random fed plasma 
insulin concentrations were also assessed in these mice for evidence of
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Figure 28. HF feeding and CrPic supplementation did not affect food or 
water consumption. Food (A) and water (B) consumption was measured once 
per week throughout the study. Weekly values obtained were divided by the 
number of days between each determination to obtain average food or water 
consumption by day values. Means values ± SEM are shown from 12 mice per 
group. While HF feeding and CrPic did not affect water consumption throughout 
most of the study, a significant difference was observed in the LF + CrPic group 
at 6 weeks post dietary intervention and in the LF - CrPic group at 7 weeks post 
dietary intervention. *, P<0.05 versus all other groups.  
 
 
 
 
 
94 
 
 
Figure 29. HF feeding promotes an impairment and CrPic supplementation 
improves glucose tolerance in C57Bl/6J mice. Intraperitoneal glucose 
tolerance tests were performed on mice following 8 weeks of dietary intervention. 
Mice were fasted for 6 hours prior to being injected at time 0 with 2 g/kg body 
weight of D-glucose (individually dosed). Blood glucose values were recorded at 
15 min, 30 min, 60 min, 90 min, and 120 min post-injection. Blood glucose curves 
(A) and area under the curve (B) are means ± SEM from 5-6 mice per group. *, 
P<0.05 versus LF (-/+) CrPic. **, P<0.01 versus LF (-/+) CrPic. ***, P<0.001 
versus LF (-/+) CrPic. #, P<0.05 versus HF (-) CrPic.  
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Figure 30. HF feeding promotes an impairment and CrPic supplementation 
improves glucose tolerance in C57Bl/6J mice. Intraperitoneal insulin tolerance 
tests were performed on mice following 8 weeks of dietary intervention. Mice 
were fasted for 6 hours prior to being injected at time 0 with 1 U/kg body weight 
of insulin (individually dosed). Blood glucose values were recorded at 15 min, 30 
min, 45 min, and 60 min post-injection and reported as % change from basal. 
Blood glucose curves (A) and area above the curve (B) are means ± SEM from 
4-6 mice per group. *, P<0.05 versus LF. **, P<0.01 versus LF. 
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hyperinsulinemia. Plasma insulin was found to be elevated in mice fed the HF 
diet, whereas this effect was not observed in animals fed a HF diet supplemented 
with CrPic (Fig. 31). Together, this data suggested that CrPic supplementation 
could improve glucose homeostasis.  
 
HF Feeding Promotes and CrPic Supplementation Prevents against 
Increased HBP Activity and Cholesterol Accrual: Given the previous in vitro 
findings, study next sought to determine if CrPic supplementation in vivo could 
prevent against the progression of insulin resistance through inhibition of 
cholesterol accrual. To test this, upon sacrifice, epididymal fat was collected for 
analyses. Adipose tissue weight was significantly increased in mice fed a HF 
diet, yet CrPic supplementation did not any have an effect on this parameter. 
However, CrPic supplementation did protect against gains in adipose tissue 
membrane cholesterol accrual (Fig. 32A). To dissect if this increase could be 
due to a transcriptional response similar to that observed in adipocytes, mRNA 
levels of HMGR were assessed. HF feeding resulted in almost a 3 fold increase 
in the mRNA levels of HMGR, whereas CrPic supplementation prevented against 
this gain (Fig. 32B). In addition, phosphorylation of AMPK was found to be 
elevated in adipose tissue of animals fed a HF diet supplemented with CrPic 
(Fig. 32C). Consistent with the possibility of CrPic inhibiting the HBP through 
activation of AMPK, immunoprecipitation experiments carried out on adipose 
tissue revealed a significant increase in O-GlcNAc of Sp1 in HF mice that was 
prevented with CrPic supplementation (Fig. 32D). Together, these data suggest 
that CrPic may be exerting beneficial effects on glucose metabolism through
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Figure 31. HF feeding promotes hyperinsulinemia. Random fed plasma was 
collected from mice following 8 of dietary intervention. An ELISA kit was used to 
measure the plasma insulin concentrations, which were determined by 
interpolation using a standard curve. Means values ± SEM are shown from 8-9 
independent experiments. *, P<0.05 LF. 
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Figure 32. CrPic ameliorates increased HBP activity in HF fed mice. 
Epididymal fat pads were collected from mice in the post-prandial state after 8 
weeks of dietary intervention. The tissue was homogenized and crude membrane 
fractions, purified RNA and whole cell lysates were prepared. Crude membrane 
cholesterol (A) was assessed and normalized to total membrane protein. Mean 
values ± SEM are shown from 6-12 mice. *, P<0.05 versus LF. The mRNA 
content of Hmgcr (B) was also determined and normalized to 36B4. Means 
values ± SEM are shown from 7-9 mice. *, P<0.05 versus control. Protein levels 
of p-AMPK (C) were determined by immunoblotting, normalized to total AMPK. 
Mean values ± SEM are shown from 6 mice. *, P<0.05 versus control. Lysates 
were immunoprecipitated for detection of O-GlcNAc on Sp1 (D). Means values ± 
SEM are shown from 5-6 mice. *, P<0.05 versus control. 
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attenuating glucose flux through the HBP, thereby inhibiting ectopic membrane 
cholesterol accumulation and impaired glucose transport.  
In summary, data from these in vitro and in vivo studies presented in Chapter 
IIC offer several novel observations. They first postulate a potential mechanism 
whereby chromium may mitigate an increased transcriptional response leading to 
the development of insulin resistance. The evidence presented here suggests 
this could be mediated through an inhibition of the HBP, either globally or through 
specific inhibition of the O-GlcNAc status of Sp1. Additionally, study conducted in 
this chapter suggests that high fat feeding in vivo, known to activate the HBP 
(356), may also promote insulin resistance through activation of cholesterolgenic 
machinery. Chromium supplementation in these mice resulted in a protection 
against the exacerbation of insulin resistance. In particular, CrPic was shown to 
activate AMPK in mice fed a HF diet. Potentially, this could inhibit HBP activity 
via phosphorylation and inactivation of GFAT (Fig. 33). Regardless of the precise 
mechanism, CrPic supplementation reduced the transcriptional activation of 
HMGR mRNA induced by HF feeding. This was also associated with a loss in the 
activity of the HBP, suggesting a new mechanism for the protective action of 
CrPic in vivo. 
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Figure 33. Model of hyperinsulinemia or HF feeding induced insulin 
resistance and protective actions of CrPic. Exposure of 3T3-L1 adipocytes to 
hyperinsulinemia induces increased HBP activity and pronounced activation of 
cholesterolgenic transcription factors such as HMGR. This results in a buildup of 
PM cholesterol which impairs distal regulation of GLUT4 translocation and 
glucose uptake. CrPic inhibits HBP activity, preventing the increased mRNA and 
protein levels of HMGR as well as PM cholesterol accrual. CrPic corrects glucose 
transport dysfunction induced by hyperinsulinemia independently of changes in 
insulin signaling. In vivo analyses of mice fed a HF diet suggest a potential role of 
this pathway in promoting cholesterol synthesis and accrual. CrPic 
supplementation in mice protects against increased HBP activity, cholesterol 
accumulation and the development of insulin resistance. The mechanism of 
action of CrPic may entail its known activation of AMPK both in vitro and in vivo, 
thereby potentiating flux through this pathway.  
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Chapter III. Perspectives 
The findings presented above in Chapter II have provided insight into the 
mechanisms by which hyperinsulinemia promotes cholesterol synthesis through 
engaging the HBP. This increased deposition of cholesterol onto the PM 
promoted an impairment in glucose transport and increased endosomal 
membrane cholesterol impaired the ability of adipocytes to efflux cholesterol, 
perhaps exacerbating this cycle. In addition, they provided evidence that this 
process also occurs to some degree in vivo, and that CrPic supplementation 
impinges on the HBP and this may explain its mechanism of action on improving 
glucose transport. The following section will consider future research questions 
that stem from the current research. It will also serve to place these current 
findings into perspective given the numerous studies in the field discussed in the 
introductory sections. As previously described, the mechanisms by which the 
intake of excessive nutrients and the composition of these nutrients can 
contribute to glucose intolerance are complex and highly interdependent. 
Findings from the present studies suggest a key role for the HBP in promoting 
many of the phenotypical features associated with insulin resistance. As 
previously highlighted, the importance of distal mechanisms involved in insulin 
signaling for GLUT4 translocation has been a subject of recent research 
(reviewed in (80, 356)). Emerging interest in understanding these mechanisms 
has been fueled by the potential to provide novel downstream therapeutic targets 
that could potentiate insulin action. In this regard, study in our lab has 
demonstrated that pathophysiologic hyperinsulinemia, thought to be an early or 
perhaps primary derangement in the etiology of disease, promotes insulin 
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resistance despite intact signaling processes (8, 12). Rather, our data suggest 
that hyperinsulinemia may promote insulin resistance through altering PM 
architecture necessary for distal components of insulin regulation of GLUT4 
exocytosis.  
To first establish the relationship between hyperinsulinemia and alterations in 
PM cholesterol content in Chapter IIA, study sought to demonstrate the role of 
low pathophysiologically relevant doses in promoting a cholesterolgenic 
response. The doses utilized in this study were consistent with other reports that 
have shown that low doses of insulin are sufficient to induce insulin resistance (8, 
12, 13, 151). Of note, while a 250 pM dose of insulin was found to result in a 
submaximal gain in PM cholesterol content, it did not have any observable effect 
on generation of HMGR. This was consistent with its inability to promote 
increases in SREBP1 content. While we did not test the effects of this dose on 
glucose uptake, we expect that it may have very modest, if any effects on this 
parameter based on the transcriptional findings. While this dose was in the upper 
quartile range of what the San Antonio Heart study of approximately 3000 
participants defined as hyperinsulinemia (135), it also fell within the range of 
fasting insulin levels (6-300 pM), suggesting this dose is too low to promote the 
derangements observed in our model system. Another consideration is that the 
3T3-L1 adipocytes have been previously reported to contain detectable levels of 
intracellular insulin degrading enzyme activity which could contribute to a gradual 
decline in insulin levels over time (357). Nevertheless, the observed effects with 
concentrations of insulin akin to those in vivo suggest that degradation rates 
were likely negligible in this system. 
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Studies showing that hyperinsulinemia can promote increases in HBP activity, 
provoking O-GlcNAc modification of Sp1, are consistent with previous reports 
that this transcription factor is modified at several residues by OGT (332). 
However, while other groups have demonstrated this modification of Sp1 in other 
cell types serves to translocate Sp1 to the nucleus (358, 359), this observation 
was not detected in current study. Yet other study has demonstrated that Sp1 is 
primarily localized to the nucleus (333), which could make any subtle changes 
difficult to detect. Nevertheless, SREBP1, known to be regulated by Sp1, was 
found to be elevated in the nuclear fractions upon treatment with 
hyperinsulinemia. Although the nuclear status of SREBP2 was also examined, as 
it plays a greater role in cholesterol synthesis, no alterations were observed in 
total or nuclear content. One report conducted in vitro binding assays with O-
GlcNAcylated Sp1 and found that the modified form of Sp1 failed to bind to 
SREBP2 (360). Whether or not this binding is necessary for a maximal activation 
of the promoter region of SREBP2 is currently unknown. The increases in 
SREBP1 content in the nucleus are hypothesized to be the consequence of 
either the increased binding of Sp1 to the promoter region of SREBP1, known to 
activate it, or perhaps due to insulin’s ability to regulate the degradation of Insig 
(182, 183). Studies with DON demonstrate a reduction in PM cholesterol content, 
favoring the former hypothesis as DON was shown to reduce the affinity of Sp1 
toward the promoter of SREBP1. Alternatively, these perturbations in the 
regulation of SREBP1 could also promote saturation of Insig, thereby increasing 
SREBP1 processing (183). 
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Since the discovery that Sp1 was a target of OGT, leading to increases in its 
stability, several reports have hypothesized that the modification of this protein 
might induce alterations in its ability to bind to DNA as well as promoter activity 
(361-363). In fact, clinical findings underscore this importance as mutations in the 
Sp1 binding sites have been observed to correlate with a significant risk for the 
development of diabetic complications such as nephropathy (364). In addition, 
sequencing analyses have revealed a novel β cell glucokinase mutation in the 
promoter region of this gene (365). In this study, the mutation was mapped to a 
binding site of Sp1, and the promoter activity in patients with this mutation was 
reduced up to 4 fold. This resulted in a shift in the set point for insulin secretion to 
7 mM, promoting fasting hyperglycemia. In the context of provoking cholesterol 
synthesis, ChIP analyses demonstrated that hyperinsulinemia-induced elevations 
in O-GlcNAc on Sp1 translated to its increased binding affinity to the promoters 
of both SREBP1 and HMGR. Previous studies have demonstrated that SREBP1 
contains 5 Sp1 binding sites which, in conjunction with SREBP1, LXR, and NF-Y, 
drive its expression (209-212). The increases in SREBP1 in the nucleus, perhaps 
caused by Sp1 mediated activation of SREBP1, could then potentially result in its 
collaboration with Sp1 bound to the HMGR promoter to further increase the 
synthesis of HMGR as well. In addition, study has demonstrated that LXR is a 
target of OGT, and this modification leads to increased expression of SREBP1 
(215). Together, these results lend further support that O-GlcNAc could play a 
central role in activating a cholesterolgenic response through the modulation of 
these critical transcription factors implicated in increased cholesterol synthesis.  
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A potential caveat to the study of precisely how O-GlcNAc modification of Sp1 
affects its function is that the RL2 antibody and Click-iT kits employed in Chapter 
IIA studies do not differentiate between the various sites that are modified by O-
GlcNAc. To date, at least 8 residues on Sp1 have been identified as targets for 
this modification, with a majority of them being in the DNA binding domain (366). 
Five of the sites for O-GlcNAc, in fact, have been identified to be in the zinc 
finger DNA binding domain of Sp1, and mutating these sites to alanine residues 
resulted in reductions in basal transcriptional activity (330). In contrast, 
mutagenesis of a peptide derived from the Sp1 activation domain also suggests 
that O-GlcNAc modification in this region may inhibit protein-protein interactions 
necessary for transcriptional activation (205, 360, 367, 368). These findings thus 
suggest a need in the field to identify precisely which residues are modified in the 
presence of hyperinsulinemia. Yet the mapping of these modified proteins 
remains limited at a technological level by the fact that O-GlcNAc is unstable 
during collision-induced dissociation in mass spectroscopy (369-371). Recently, 
new methods have been implemented to assist in this process, in particular 
chemical/enzymatic photochemical cleavage techniques that introduce a 
photochemical cleavable biotin probe on O-GlcNAc residues (372-375). This 
method and other similar enzymatic labeling methods are estimated to have a 
sensitivity in the low femtomole range, overcoming the limitation of needed 
milligram quantities of protein to detect sites of glycosylation. Future studies are 
thus warranted that will examine precisely what residues are modified by O-
GlcNAc and how they affect protein-protein interactions and DNA binding in the 
context of hyperinsulinemia-induced insulin resistance.  
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The observation in Chapter IIA that HMGR protein levels are elevated by 
hyperinsulinemia treatment and corrected by HBP inhibition is also somewhat 
perplexing given the intense regulatory mechanisms discussed in the introduction 
to maintain precise cholesterol homeostasis. An initial hypothesis was that 
perhaps cholesterol levels were increased solely at the PM such that endosomal 
cholesterol content was normal, preventing the degradation of HMGR known to 
occur when endosomal cholesterol levels rise. Yet studies presented in Chapter 
IIB refute this hypothesis and rather suggest global increases in cellular 
cholesterol. Future research endeavors could seek to assess the rate of turnover 
of HMGR, while also examining the status of other proteins involved in 
cholesterol synthesis. A hypothesis favored in this regard is that HMGR turnover 
is likely increased in cells treated with hyperinsulinemia, but perhaps the 
increased rate of synthesis overcomes the degradation. Another potential 
explanation for the increase in cholesterol is through the process of 
macrolipophagy in which cholesterol esters and triglycerides stored in lipid 
droplets become mobilized (376). Indeed, study from Timothy Osborne’s lab 
suggests that this process can contribute to increases in cellular cholesterol 
content (377). Yet these studies suggested that this process is mediated by 
SREBP2 and occurs in situations of sterol depletion. Nevertheless, whether 
SREBP1 could play a role in this process and if the HBP could provoke this 
aberrant response in adipocytes despite adequate cholesterol content is a 
subject of research. Importantly, inhibition of the HBP with DON attenuated 
cholesterol synthesis at the level of transcription, providing further evidence that 
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the insulin-induced defects are likely functioning at the transcriptional level to 
promote gains in HMGR and PM cholesterol content.  
Data presented in Chapter IIA also suggest a central role of Sp1 in triggering 
the cholesterolgenic response as indicated by the experiments conducted using 
mithramycin. Study has previously demonstrated a major role of Sp1 in 
regulation of resistin expression (331, 378). In this regard, mithramycin has also 
been shown to inhibit the transcription and secretion of interleukin 6 (IL-6), a 
pleiotropic cytokine known to impair glucose-stimulated insulin secretion in 
rodents (379-381), and insulin action in adipocytes (382-384). In the current 
studies, mithramycin abrogated the hyperinsulinemia-induced increases in 
HMGR protein levels, restored PM cholesterol and F-actin structure, and 
improved glucose transport rendered impaired by hyperinsulinemia. The 
observed effects of mithramycin were not attributable to a loss of O-GlcNAc on 
Sp1 as this was found to be elevated despite mithramycin treatment. This data 
suggested a potential critical role of Sp1 in the dysregulation of cholesterol 
synthesis that occurs with altered nutrient delivery to adipocytes.  
 Together, the data presented in Chapter IIA suggest that Sp1 may be a 
potential therapeutic target for improving insulin sensitivity. Other study with 
mithramycin has shown that it may have beneficial effects on hepatic insulin 
signaling through its negative regulation of protein phosphatase 1B (385). As 
previously mentioned, Sp1 binding sites have also been found on a host of 
promoters encoding adipokines including leptin, resistin, and adiponectin (331, 
363, 364, 378). Of particular interest is the finding by one study that suggests 
PPARγ agonists specifically inhibit O-GlcNAc modification of Sp1 (331), thereby 
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exerting a positive effect on insulin sensitivity in adipocytes. In this regard, we 
hypothesized that HBP inhibition could protect against insulin resistance through 
inhibiting Sp1 modification and that increased HBP might be responsible for 
impairments in cholesterol efflux processes in addition to impaired glucose 
transport.  
 The studies presented in Chapter IIB were performed in direct collaboration 
with a fellow post-doc in the lab, Whitney Sealls. In Chapter IIB, the role of 
cholesterol accrual in mitigating cholesterol efflux processes in adipocytes was 
further examined. In addition, the role of CrPic treatment in alleviating these 
cellular derangements and its potential mechanism were explored. The basis for 
these CrPic studies comes from early studies in humans suggesting that CrPic 
deficiency is linked to reductions in circulating HDL (386). Additionally, brewer’s 
yeast in human trials has been shown to improve plasma HDL concentrations 
(220, 221). While still fragmentary, even Nanne Kleefstra, who has suggested in 
several reports that human CrPic trials should conclude no effect on any 
parameter of glucose metabolism, observed a trend toward increased HDL in 
patients receiving CrPic intervention (1.15 ± 0.26 mmol/l in placebo and 1.47 ± 
0.54 mmol/l in the intervention group), lending support for a potential beneficial 
role in humans (387). Regardless, an emerging appreciation is that total HDL 
measurements are misleading in understanding its cardioprotective actions, as 
the ABCA1-generated pre-β-1 HDL particle likely represents the “functional” 
subfraction (339).  
 Mechanistically, it was determined that CrPic supplementation improves 
cholesterol efflux processes in adipocytes, perhaps directly through lowering 
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endosomal cholesterol content and thereby allowing for appropriate extraction of 
Rab8 by GDI. Support for the role of endosomal cholesterol accrual in this 
process comes from the fact that CrPic was associated with a correction of 
endosomal membrane cholesterol levels and that HBP inhibition also improved 
cholesterol efflux. Additionally, numerous studies have demonstrated that 
endosomal motility is impaired in NPC as well as cells treated with U18666A, a 
cholesterol transport inhibitor (388-390). In these studies, it was suggested that 
the impairment was due to an inhibition of the membrane-cytosol cycling of 
Rab7, resulting in reduced dynamics. Moreover, other study has further 
supported this hypothesis through the examination of viral infectivity. In one such 
study, the Vesicular Stomatitis Virus (VSV) was utilized, which infects cells from 
the endosomes (391). In these studies, it was found that the action of this virus 
was significantly attenuated in U18666A treated cells, suggesting that cholesterol 
accumulation impairs membrane dynamics. Yet this treatment did not affect the 
fusion of the virus with the endosomes, but rather VSV infectivity, presumably 
because the capsids released into the endosomal membrane remained trapped 
due to impaired trafficking processes. As such, future studies with regard to 
cholesterol efflux could be performed to specifically determine if increases in 
endosomal cholesterol content impair the cycling of Rab8. Of particular interest is 
whether extraction of Rab8 by GDI may become impaired, as others have shown 
occurs with Rab9 during cholesterol accumulation observed in NPC (341).  
 Of clinical importance, the development of pro-atherogenic foam cells is 
thought to result from the impaired ability of macrophages to efflux cholesterol via 
ABCA1 and ABCG1 (392). If this efflux of cholesterol is sufficient to rid oxidized 
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cholesterol generated from reactive oxygen species in the neointima, the 
development of atherosclerosis can be circumvented. In this context, a loss in the 
generation of pre-β-1 HDL by adipocytes could contribute to the progression of 
atherosclerosis and the development of coronary artery disease (CAD). A 
potential caveat to translating this finding to humans is data by Ishida that 
suggests that total pre-β cholesterol makes up as much as 63% of plasma ApoA-
I in lipoprotein disorders such as familial hypercholesterolemia, lipoprotein lipase 
deficiency, LCAT deficiency, and familial combined hyperlipidemia (393). In 
addition, since the discovery of methods to segregate and resolve pre-β-1 HDL 
through nondenaturing electrophoresis, a paradoxical connection between 
elevated levels of pre-β-1 HDL, CAD, and increased carotid intima-media 
thickness has been observed (394). Several other studies have reported this 
elevation in patients with coronary heart disease (395, 396), and a recent clinical 
trial involving 1255 subjects suggests this fraction as an independent risk factor 
for this disease as well as myocardial infarction (397). Importantly, however, this 
accumulation itself is postulated to be compensatory rather than causative in this 
regard as study suggests that the accumulation may result from a defect in LCAT 
activity seen in patients with CAD (398). Interestingly, exercise, known to 
stimulate AMPK activity, has been shown in type 2 diabetics to enhance the 
conversion of pre-β-1 HDL into its more mature forms, thereby potentially leading 
to an improvement in cardiovascular outcomes (399). These findings suggest 
future studies with chromium to determine if its activation of AMPK may not only 
improve the generation of pre-β-1 HDL for macrophage efflux but also increase 
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its conversion by LCAT, thereby potentially improving neointimal thickness, 
macrophage efflux, and CAD. 
 Of importance for future study is the potential that impaired ABCA1-mediated 
cholesterol efflux may potentiate the pathogenesis of diabetes through further 
accumulation of cellular cholesterol content. Additionally, defects in ABCA1-
mediated cholesterol efflux in β cells are known to contribute to impaired insulin 
secretion (222). In fact, a small study of patients with Tangier’s disease, caused 
by a mutation leading to a defective ABCA1 transporter, revealed impaired 
glucose tolerance and insulin secretion (400). An important direction of future 
research will be to generate a unique ABCA1 inducible knockout mouse specific 
to adipose tissue or skeletal muscle. This will corroborate current cell culture 
analyses presented in Chapter IIA and B which suggest elevations in cholesterol 
content may impair glucose uptake and cholesterol efflux processes.  
In Chapter IIC, the mechanism(s) of action of CrPic on benefiting glucose 
metabolism was examined in vitro and in vivo. These studies suggested a novel 
mechanism whereby CrPic my impart protection against glucose intolerance 
through modulation of cholesterol synthesis. Further, data presented in this 
section sought to test whether CrPic inhibits glucose flux through the HBP, 
thereby decreasing O-GlcNAc of Sp1 and inhibiting transcriptional activation of 
cholesterol synthesis. In line with cell culture studies, animal data presented 
support the possibility that, in part, cholesterol accumulation in vivo may arise 
from an increase in cholesterol synthesis provoked by elevations in HBP activity.  
An important finding in these studies was that neither CrPic nor 
hyperinsulinemia had any effect on distal components of insulin signaling. While 
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proximal insulin signaling was not examined in the current study, previous reports 
have shown that neither CrPic nor hyperinsulinemia alone promoted amplification 
or impairment, respectively, in these proteins (8, 12, 21, 22), making it unlikely 
that a combinatorial effect would be observed proximally that would not 
contribute to a distal defect. These findings are also consistent with the idea that 
distal components of GLUT4 regulation at or near the PM are important targets 
for impairments in insulin action (80). 
The findings in Chapter IIC implicate that CrPic may impinge upon the HBP 
through its activation of AMPK, observed in both HF fed animals supplemented 
with CrPic and in cell culture systems. While recent reports suggest that AMPK 
may phosphorylate GFAT and inhibit HBP activity in this manner (309, 310), this 
process was not examined in the current study. Of interest, however, were 
parallel studies conducted in L6 myotubes which highlight a requirement for 
AMPK in this micronutrient’s mechanism of action. In these studies, myotubes 
treated with CrPic displayed elevated AMPK activation, as evidenced by 
increased phosphorylation of the catalytic alpha subunit at threonine 172. The 
effect of CrPic-induced phosphorylation of AMPK was demonstrated to be more 
robust in cells that were cultured in hyperinsulinemic conditions. To determine if 
AMPK activity was required for the beneficial aspects of CrPic action on glucose 
metabolism, siRNA technology was employed to knock down the catalytic α 
subunit of AMPK. This knockdown experiment resulted in a reduction in the 
detection of AMPK protein by approximately 80% (Fig. 34). Consistent with 
AMPK mediating the action of CrPic, in cells transfected with scramble 
oligonucleotides, CrPic treatment was able to restore a loss in GLUT4 
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Figure 34. AMPKα knockdown efficiency. Following transient transfection with 
control oligonucleotides (siScramble) or those targeting the α catalytic subunit of 
AMPK (siAMPK), whole cell lysates were prepared and subjected to 
immunoblotting to assess total protein content of AMPK as a measure of 
efficiency of the knockdown. Means values ± SEM are shown from 4 
independent experiments.  
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redistribution to the PM induced by hyperinsulinemia (Fig. 35A). Contrary to this, 
cells that were treated with siAMPK had a marked reduction in the ability of 
insulin to stimulate GLUT4 translocation that was not corrected by treatment with 
CrPic (Fig. 35B). To corroborate these findings and investigate the functionality 
of GLUT4, glucose uptake assays were performed. As observed with the GLUT4 
translocation assays, an impairment was seen in the responsiveness of insulin to 
stimulate glucose uptake in the presence of hyperinsulinemia (Fig. 35C). This 
was corrected with CrPic treatment in these control transfected cells, but not in 
the cells in which AMPK was knocked down with siAMPK (Fig. 35D). Importantly, 
insulin signaling remained intact in these knockdown cells, and CrPic did not 
result in the phosphorylation of residual AMPK. This data thus strongly supports 
a causative role of AMPK in mediating the beneficial aspects of CrPic on glucose 
metabolism. This is in line with a recent study demonstrating that inhibition of 
AMPK with compound C blunts the effect of CrPic inhibition of resistin secretion 
in adipocytes (281). Future studies should therefore determine if this beneficial 
aspect of CrPic involves the inactivation of GFAT. 
Our studies using HF fed mice to induce the development of insulin 
resistance lends further support to the idea that CrPic could counter against 
elevated HBP activity induced by HF feeding. Indeed, in transgenic mice 
overexpressing GFAT, HF feeding is not additive in causing insulin resistance, 
consistent with a shared pathway (401). In addition, GFAT overexpression 
specifically in the adipose tissue of mice results in increased serum leptin, 
decreased adiponectin, increased fat synthesis, as well as skeletal muscle insulin 
resistance as assessed by both hyperinsulinemic-euglycemic clamp as well as
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Figure 35. AMPKα is necessary for the protective actions of CrPic on 
insulin responsiveness. Following transient transfection with control 
oligonucleotides (siScramble) or those targeting the α catalytic subunit of AMPK 
(siAMPK), GLUT4 myc and 2-DG transport assays were performed. L6 myotubes 
were pretreated with or without 10 nM CrPic for 16 h. After 4 h of pretreatment, 
cells were treated with or without 5 nM insulin for 12 h. Following treatments, 
cells were placed in serum free media for 1 h. During the last 20 min, cells were 
incubated with 100 nM insulin to stimulate GLUT4 translocation and glucose 
uptake. The fold increase in insulin-stimulated GLUT4 myc immunofluorescence 
was determined in siScramble (A) and siAMPK (B) as well as 2-DG transport in 
siScramble (C) and siAMPK (D) cells. Means values ± SEM are shown from 6-8 
independent experiments. *, P<0.05 versus insulin-stimulated control. 
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2-DG uptake from hind limb muscle (156, 158). These studies, coupled to 
thoseinducing overexpression of GLUT1 (402), suggest a prominent role of 
elevations in HBP pathway in adipose tissue in promoting derangements in 
whole body glucose disposal.  
 In terms of human health, these data presented in Chapter IIC suggest a 
novel, putative mechanism by which CrPic could be beneficial to glucose 
metabolism via countering PM stress. While clinical trials suggest a beneficial 
effect of CrPic in diabetics, it may be possible that CrPic supplementation has an 
effect to counter dysregulation in membrane fluidity and that this incremental 
affect may become lost later in disease progression when other factors further 
dampen insulin sensitivity. Alternatively, other drugs patients are taking, such as 
metformin, known to activate AMPK, may mask the effects of CrPic action. 
Further, well-designed longitudinal studies are thus needed in insulin resistant, 
non-diabetic patients to help better characterize the role of this micronutrient in 
alleviating insulin resistance.  
 
Conclusion  
 In conclusion, together the data presented in Chapter II provide novel 
mechanistic insight into how hyperinsulinemia may promote cholesterol 
accumulation associated with impaired glucose and lipoprotein metabolism. In 
this context, the data has indicated an important role for alterations in HBP 
activity in mediating these consequences. In addition, these data demonstrate 
that CrPic treatment can alleviate these alterations in cholesterol efflux and 
glucose transport, as well as improve glucose tolerance and insulin sensitivity in 
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a diet-induced mouse model of insulin resistance. Data presented in Chapter IIA 
mechanistically link elevations in HBP activity in promoting a transcriptional 
response leading to increases in cholesterol synthesis. Inhibition of this pathway 
or direct inhibition of a direct target of this pathway, Sp1, prevented against this 
response and restored insulin responsiveness in adipocytes. Expanding on these 
findings, studies presented in Chapter IIB suggest that HBP-induced cholesterol 
accrual may impair the appropriate trafficking of ABCA1, perhaps due to an 
alteration in the proper extraction of Rab8. These studies also highlighted a 
beneficial role of CrPic treatment or HBP inhibition in decreasing endosomal 
cholesterol content, strengthening the hypothesis that CrPic may inhibit 
cholesterol synthesis through altering flux through the HBP. In this manner, CrPic 
also rescued an impairment in cholesterol efflux induced by hyperinsulinemia. In 
Chapter IIC, it was found that CrPic appears to inhibit flux through this pathway 
both in vitro and in vivo. This was associated with a loss of transcriptional 
activation of cholesterol synthesis, restoration of PM cholesterol, and 
improvement in glucose uptake. CrPic supplementation in mice was found to 
blunt the development of insulin resistance induced by HF feeding, perhaps 
mediated in part through the same mechanism. These data suggest that CrPic, 
through AMPK activation, suppresses cholesterol synthesis through inhibition of 
the HBP, thereby lowering membrane cholesterol that disrupts F-actin structure 
and induces insulin resistance in adipocytes and adipose tissue.  
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Chapter IV. Experimental Procedures 
 
Cell Culture and treatments 
Murine 3T3-L1 preadipocytes were purchased from Dr. Howard Green 
(Harvard Medical School) and cultured as previously described (403). Briefly, 
3T3-L1 preadipocytes were cultured in DMEM containing 25 mM glucose and 
10% calf serum in at 37°C at a 10% CO2 atmosphere. Confluent cultures were 
induced to differentiate into adipocytes by incubation of the cells with DMEM 
containing 25 mM glucose, 10% fetal bovine serum, 1 µg/ml insulin, 1 mM 
dexamethasone, and 0.5 mM isobutyl-1 methylxanthine. After 4 days, the 
medium was changed to DMEM containing 25 mM glucose, 10% fetal bovine 
serum, and 1 µg/ml insulin for an additional 4 days. All studies were performed 
on adipocytes between 8 and 12 days post initiation of differentiation. The cells 
were left untreated or treated for 12 h with insulin (250 pM - 5000 pM) in serum 
free DMEM medium. Overnight insulin incubations were limited to 12 h to 
minimize complications on glucose transport due to glucose deprivation (404). 
Several pretreatment conditions were also tested. These pretreatments were for 
16 h and included 20 µM DON, 100 nM mithramycin, and 10 nM CrPic. 
Additionally, study also utilized a 12 h treatment with 300 µM methyl-β-
cyclodextrin. Studies utilizing AICAR were conducted by incubating cells in the 
presence of AICAR for the last 45 min of the study. Acute insulin stimulation was 
performed by treating adipocytes with a 100 nM dose of insulin during the last 5 
min for insulin signaling or 30 min for glucose transport analyses.  
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 For studies in L6 myotubes, rat L6 muscle cells stably expressing GLUT4 
that carries an exofacial myc-epitope (provided by Dr. Amira Klip) were cultured 
as previously described (11). Briefly, myoblasts were cultured in an α-minimum 
essential medium (α-MEM) containing 5.5 mM glucose and 10% fetal bovine 
serum. Cells were differentiated into multinucleated myotubes by placing them in 
α-MEM containing 5.5 mM glucose and 2% fetal bovine serum. All studies were 
performed on myotubes between 4 and 6 days post-initiation of differentiation. 
The cells were left untreated or treated for 12 h with insulin (5 nM) in DMEM 
containing 5 mM glucose and 1% fetal bovine serum. Pretreatment included the 
incubation of myotubes for 16 h with 100 nM CrPic. Acute insulin stimulation was 
performed by treating myotubes with a 100 nM dose of insulin during the last 20 
minutes for glucose transport analyses. 
 
Mice, diets and CrPic supplementation 
 Male C57Bl/6J mice (age 4 weeks) were obtained (Jackson Laboratory, Bay 
Harbor, Maine) and were singly housed in a light and temperature-controlled 
animal facility (12/12 (light/dark), 20°C). All mice had free access to water with or 
without CrPic that provided approximately 8 µg/kg body weight per day. Based 
on the fact that commercially available nutritional supplements generally contain 
CrPic at 200 to 600 µg/kg per day and an average human mass of 75 kg, the 
supplements provide 600 µg/kg per day. All animals received standard laboratory 
chow for 2 weeks followed by a LF diet containing 20% kcal from protein, 70% 
kcal from carbohydrates, and 10% kcal from fat (D01030107, Research Diets 
Inc., New Brunswick, NJ). This LF, as well as the HF diet represented modified
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forms of the standard LF (D12450B) and HF (D12451) diets with adaptions 
regarding type of fat (palm oil instead of lard) and carbohydrates to better mimic 
the FA and carbohydrate composition of the average human diet in Western 
societies. The mice were fed the modified LF diet for 3 weeks to adapt. After this 
5 week total acclimation period, mice were either left on the LF diet or switched 
to the HF diet containing 20% kcal from protein, 35% kcal from carbohydrates, 
and 45% kcal from fat (D01030108). By addition of chromium sulfate to the 
chromium-free diets, both the LF and HF test diets were controlled to contain an 
equal amount of chromium (1.9 mg/kg diet). Note that the energy density of all 
nutrients, except fat and starch, is equal. All animal protocols were approved by 
the Indiana University School of Medicine Institutional Animal Care and Use 
Committee.  
 
IPGTT and IPITT  
 C57Bl/6J mice were fasted for 6 hours (from 8:00 a.m. to 2:00 p.m.). Mice 
were then injected intraperitoneally with 2 g/kg D-glucose (individually-dosed) at 
time 0 for the IPGTT and blood was obtained vial tail collection at 15, 30, 60, 90, 
and 120 minutes post-injection of glucose. Mice were injected with 1.0 unit of 
insulin/kg (individually-dosed) at time 0 for IPITT, and blood was obtained via tail 
collection at 15, 30, 45 and 60 minutes post-injection of insulin. Blood glucose 
was analyzed using the Abbott Animal Health AlphaTRAK blood glucose meter 
(Abbott Laboratories, Abbott Park, IL).  
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Insulin ELISA 
 Upon sacrifice, blood was collected from mice by cardiac puncture in the fed 
state. Plasma was obtained by centrifuging blood samples at 4°C for 15 minutes 
at 2000 revolutions per minute using a table top centrifuge. Plasma insulin 
concentrations were determined using the low range assay (0.1-6.4 ng/ml) 
protocol from the Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem. Inc., 
Downers Grove, IL).  
 
Subcellular fractionation  
 Purified adipocyte endosomal membrane, cytosol, and plasma membrane 
fractions and epididymal adipose crude membrane fractions were prepared as 
described previously (405). Purified fractions were resuspended in a detergent 
containing lysis buffer and recovered protein content was determined using the 
Bradford method. Nuclear extracts were collected as previously described (406). 
Briefly, 3T3-L1 adipocytes were washed with PBS and collected in 2.0 ml of 
hypotonic buffer (10 mM HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1mM DTT 
containing 10 mM leupeptin, 2 mM pepstatin, 2 mM aprotinin, and 0.5 M PMSF). 
Lysates were prepared by passing the cells through a 22-gauge needle 5 times, 
followed by centrifugation at 800 g for 10 min at 4°C. The pellet was then 
resuspended in 200 µl of buffer C (10 mM HEPES, pH 7.4, 0.42 M NaCl, 25% 
glycerol (v/v), 1.5 mM MgCl2, 0.5 mM EDTA containing 10 mM leupeptin, 2 mM 
pepstatin, 2 mM aprotinin, and 0.5 M PMSF). Proteins were extracted from the 
nuclei with gentle vortexing for 15 s every 10 min for 1 h. The mixture was then 
centrifuged at full speed in a microcentrifuge at 4°C and the supernatant 
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consisting of nuclear proteins was collected for Bradford method to determine 
protein content. 
 
Actin analyses 
Actin labeling of 3T3-L1 adipocytes was performed as previously described 
(7). Briefly, after treatments cells were fixed in a 4% paraformaldehyde 0.2% 
Triton X 100 (v/v) solution containing PBS. Following fixation, cells were 
incubated with 5 µg/ml of FITC-conjugated phalloidin for 2 h. All cell images were 
obtained using a Zeiss LSM 510 NLO confocal microscope (Carl Zeiss, 
Thornwood, NY), and all microscope settings were identical between treatment 
groups. Immunofluorescent intensity was normalized to intensity from Syto60, a 
fluorescent nucleic acid stain (Molecular Probes).  
 
Cholesterol analyses  
3T3-L1 adipocytes PM or adipose tissue crude membrane  pellets obtained 
from differential centrifugation were resuspended in 0.2 ml of HES buffer, and 
cholesterol content was assayed using the Amplex Red Cholesterol Assay Kit 
(Molecular Probes), as previously described (7). Briefly, 0.15 ml of the 
resuspended PM pellet was vigorously mixed with 3.0 ml of chloroform-methanol 
(2:1 v/v) for 10 min to extract cholesterol. The mixture was then centrifuged at 
580 x g for 10 min followed by collection of 1 ml of the lower phase which was 
evaporated at 100°C for 10 min. The residue was then reconstituted with 0.1 ml 
of an isopropranol-Triton X solution (10:1 v/v) and 0.05 ml of the sample was 
incubated with 0.05 ml of Amplex Red cholesterol reaction buffer at 37°C for 30 
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min. After incubation, the absorbance was measured at 600 nm. Cholesterol 
content was normalized to total PM or crude membrane protein.  
 
Protein analyses  
After collection of cellular or adipose tissue lysates, membrane, cytosolic, or 
nuclear fractions, 30-50 µg of protein were separated on a 7.5% SDS-
polyacrylamide gel (6% SDS for ABCA1 analyses), and resolved fractions were 
transferred to nitrocellulose (Bio-Rad, Hercules, CA). Membranes were then 
probed utilizing antibodies for HMGR (Millipore), SREBP2 (Abcam), SREBP1 
(Abcam), ABCA1 (Abcam), Rab8 (BD Biosciences), or AMPK (Cell Signaling) 
followed by an IRDye™ 700DX or 800DX conjugated secondary (Rockland). 
Immunoblots were quantitated using a LI-COR Odyssey infrared imaging system. 
Immunoblots were normalized to β-actin (Cytoskeleton) for equal protein loading. 
For immunoprecipitation experiments, lysates from 3T3-L1 adipocytes or adipose 
tissue were collected using an NP-40 lysis buffer (25 mM Tris, pH 7.4, 137 mM 
NaCl, 10 mM NaPP, 1% NP40, 1% glycerol, containing 10 mM leupeptin, 2 mM 
pepstatin, 2 mM aprotinin, and 0.5 M PMSF). Whole cell lysates were then 
prepared by centrifugation at 14,000 rpm at 4°C for 15 min. The Bradford assay 
was performed to ensure equal protein loading for IP analysis. 
Immunoprecipitation was carried out overnight with 1.25 mg protein and 2 µg of 
antibody for Sp1 (Santa Cruz). Samples were then incubated with 80 µl of protein 
G agarose (Roche) for 1 h with rotation at 4°C. Protein complexes were pelleted 
by centrifugation at 14,000 rpm at 4°C for 10 min, washed with NP-40 lysis 
buffer, and eluted with 200 µl LSB containing β-mercaptoethanol and 0.1 M DTT. 
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Samples were then run on a 7.5% SDS-polyacrylamide gel and immunoblotted 
with an RL2 antibody (Thermo Scientific). For Click-iT O-GlcNAC enzymatic 
labeling experiments, lysates were immunoprecipitated as described above. Prior 
to elution, samples were resuspended in 200 µl 1% SDS, 20 mM HEPES at pH 
7.9 and labeled with biotin-alkyne using the Click-iT O-GlcNAc enzymatic 
labeling system and protein analysis detection kits (Invitrogen). The 
immunoprecipitated samples were then eluted as described above. Samples 
were then run on a polyacrylamide gel and analyzed using a streptavidin 
antibody (Abcam).  
 
RNA analyses 
3T3-L1 adipocytes were lysed using a Qiagen QIAshredder and RNA was 
isolated using an RNeasy mini kit (Qiagen). For adipose tissue analyses, RNA 
was collected using the RNeasy lipid tissue mini kit (Qiagen) Purified RNA was 
reverse transcribed using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Reactions were performed in a 96-well plate using the ABI 
Prism 7000 Sequence Detection System (Applied Biosytems). Each reaction 
contained the following: 12.5 µl of SYBR GREEN (Applied Biosystems), 200 nM 
of each primer, 3 µl of cDNA, and RNase free water to a total volume of 25 µl. 
The PCR conditions used were 95°C for 15 min, followed by 40 cycles of 95°C 
for 15 s, 60°C for 40 s. Cycle threshold values were obtained and normalized to 
36B4. The ∆∆Ct method was used to determine relative expression levels. 
Primers utilized for these and ChIP analyses (below) are shown in Appendix A.  
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ChIP analyses 
After treatments, 3T3-L1 adipocytes were fixed with 1% formaldehyde in PBS 
for 10 min. The reaction was then quenched with 50 mM glycine in PBS and 
subsequently washed two times with ice-cold PBS. Cells were then scraped in 
PBS plus protease inhibitor cocktail and centrifuged for 2 min at 2,000 rpm. The 
pellet was resuspended in 500 µl ChIP lysis buffer (50 mM Tris pH 8.1, 10 mM 
EDTA, 1% SDS plus protease inhibitor cocktail) and sonicated (10 pulses of 30 s 
on, 30 s off) and centrifuged at 14,000 rpm at 4°C for 10 min. Chromatin size was 
checked by running on a non-denaturing polyacrylamide gel to ensure that the 
average size was between 200-500 bp. Fragmented chromatin preparations (100 
µl) were then diluted with ChIP dilution buffer (Millipore), and an input sample 
was collected. Samples were precleared with 60 µl of ChIP blocked protein G-
Agarose beads (Millipore) for 1 h at 4°C with rotation prior to immunoprecipitation 
with antibodies to Sp1 (Santa Cruz) or IgG (Millipore) overnight. Samples were 
then incubated with 60 µl of protein G-Agarose beads for 1 h, then protein-DNA 
complexes collected by centrifugation. Immunoprecipitates were washed in low 
salt immune complex wash buffer, high salt immune complex wash buffer, LiCl 
immune complex wash buffer, and 2 washes in TE buffer (Millipore, 5 min each). 
Immune complexes were then eluted with elution buffer (1% SDS, 100 mM 
NaHCO3), and reverse cross-linked with the addition of 8 µl of 5 M NaCl at 65°C 
overnight. Successful immunoprecipitation was ensured by running samples on a 
polyacrylamide gel and probing with the Sp1 antibody. After RNase A and 
Proteinase K treatment, phenol/chloroform was used to purify DNA which was 
used as a template for qPCR under the following conditions: 15 min at 95°C 
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followed by 35 cycles of 15 s at 95°C, 30 s at 50°C, and 34 s at 60°C. The fold 
enrichment method was used to quantitate Ct values. Subsequent non-
denaturing gel electrophoresis was performed on samples subjected to qPCR to 
confirm the product. Dissociation curves were also performed and an additional 
aliquot of DNA was subjected to nanodrop to ensure purity, 260/280 was 1.8-2.0.  
 
Plasmids & luciferase reporter assay  
For luciferase assays, the proximal promoter sequence (-284 to +36) of 
Hmgcr was PCR amplified from mouse genomic DNA. Promoter fragments were 
sequenced and cloned into pGL2B luciferase reporter plasmids (Promega, 
Madison, WI). Differentiated adipocytes were electroporated (0.16 kV and 960 
µF) as previously described (7). Briefly, cells were trypsinized and pelleted by 
centrifugation at 1000 rpm. Pellets were resuspended in PBS and re-pelleted. 
Pellets were then resuspended in 1.0 ml PBS. For transfection, 50 µg of Hmgcr 
pGL2B and 50 µg of phrl-minTK (Renilla) plasmid were used at a concentration of 
approximately 1 X 107 cells/0.5 ml. A single pulse was then applied using a Gene 
Pulser (Bio-Rad #1652076). The electroporated cells were then allowed to 
recover and plated into a 24 well plate. Experiments were started 16-18 h after 
electroporation by placing cells in the appropriate medium. After treatments, cells 
were lysed and assayed for promoter activity using the dual-luciferase reporter 
assay system (Promega, Madison, WI). Firefly luciferase activities were 
normalized to Renilla activity to control for differences in transfection efficiency.  
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GLUT4 analyses 
 In L6 myotubes, GLUT4 myc labeling was performed as previously described 
(12). Briefly, myotubes were fixed with 2% paraformaldehyde/PBS. After fixation, 
cells were then blocked for 1 h at room temperature in Odyssey Blocking Buffer 
(LI-COR Biosciences, Lincoln, NE). Samples were incubated in a 1:50 dilution of 
primary antibody overnight at 4°C, followed by incubation at room temperature 
with infrared-conjugated secondary antibody for 1 h. Images were collected and 
quantified with the Odyssey system. Immunofluorescent intensity was normalized 
to intensity from Syto60, a fluorescent nucleic acid stain. 
 
Glucose transport assay  
Glucose uptake assays were performed as previously described (7). Briefly 
treated 3T3-L1 adipocytes were incubated in a KRPH buffer (136 mM NaCl, 20 
mM HEPES, pH 7.4, 5 mM sodium phosphate, pH 7.4, 4.7 mM KCl, 1 mM 
MgSO4, 1 mM CaCl2) for 15 min. Cells were then left untreated or stimulated with 
100 nM insulin for 30 min and exposed to 50 µM 2-DG containing 0.5 µCi 2-[3H] 
deoxyglucose (Perkin Elmer) in the absence or presence of 20 µM cytochalasin 
B. For L6 myotubes, treated cells were incubated in glucose-free buffer (125 mM 
NaCl, 5 mM KCl, 1.8 mM CaCl2, 2.6 mM MgSO4, 25 mM HEPES, 2mM pyruvate, 
and 2% BSA) for 30 minutes, after which stimulation was carried out with 100 nM 
insulin for 20 min. Cells were then exposed to 2-DG containing 0.055 µCi/µl 2-
[3H] deoxyglucose and nonspecific uptake was quantitated via cell associated 
radioactivity in the presence of 20 µM cytochalasin B. For both cell types, after 10 
min, uptake was terminated by aspiration and quenched with the addition of 1.0 
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ml of 10 µM cytochalasin B or 4 quick PBS washes for adipocytes and myotubes, 
respectively. Cells were then solubilized in 0.2 N NaOH or 1.0 N NaOH and [3H] 
was measured by liquid scintillation. Counts were normalized to total cellular 
protein, determined by the Bradford method. 
 
Cholesterol efflux  
 ApoA-I-mediated cholesterol efflux was determined as previously described 
(407). Briefly, adipocytes were labeled with 0.5 µCi/ml 3H-cholesterol (Sigma 
Aldrich) for 24 hours in 25 mM glucose DMEM containing 0.2% BSA. Cells were 
then washed and treated as described. Cells were then incubated in 25 mM 
glucose DMEM containing 0.2% BSA and 10 µg/ml lipid-free ApoA-I for 4 hours. 
This was followed by measuring 3H-cholesterol in the medium and in the cells. 
The percentage of acceptor-specific efflux was calculated using the following 
equation: medium/(medium+cells). Values obtained in the absence of acceptor 
were subtracted to account for non-specific 3H-cholesterol efflux/leakage.   
 
siRNA design and transfection  
Three independent oligonuceotide sequences, designed and purchased from 
Ambion (Austin, TX), were tested for each of the two alpha subunit isoforms. The 
oligonucleotides with the highest knockdown efficiency for α1 and α2 were 
respectively: CGA GUU GAC UGG ACA UAA ATT (siRNA ID#: 194424) and 
GCA ACU AUC AAA GAC AUA CTT (siRNA ID#: 194794). As these cells 
express both alpha isoforms, the combination of the two nucleotides led to the 
greatest knockdown efficiency. Ambion’s Negative Control #1 siRNA (Cat 
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#:4635) was used as a control in all experiments. For all knockdown experiments 
cells were seeded as described. Cells were first transfected at approximately 48 
h post seeding (or ~60% confluency). A calcium phosphate transfection protocol 
was utilized as follows, 60 pmol of siRNA was added to siRNA mix: 15 µl ddH2O, 
15 µl Buffer A (0.5 M CaCl2, 0.1 M HEPES (pH 7.0)) and 30 µl Buffer B (0.28 M 
NaCl, 0.75 mM NaH2PO4, 0.75 mM Na2HPO4 and 0.05 M HEPES (pH 7.0)) and 
after 10 min at room temperature, the siRNA mix was added to each well of a 12 
well plate containing 600 µl DMEM + 5% FBS and incubated 12-16 h. Following 
12-16 h incubation, media was aspirated and replaced with DMEM + 2% FBS. 
Additional transfection was repeated 72 h after initial transfection. Cells were 
treated and assayed 72 h after final transfection. 
 
Statistics 
All values are presented as means ±SEM. The significance of differences 
between means was evaluated by one-way repeated measures analysis of 
variance (ANOVA). Where differences among groups were indicated, the 
Newman-Keuls post-hoc test was used for post hoc comparison between groups. 
Differences between two groups were analyzed by the Student’s two-tailed t-test 
for independent samples. GraphPad Prism 5 software was used for all statistical 
analyses. P <0.05 was considered significant. 
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Appendix A. Primers Utilized for PCR amplification in the current studies. 
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June 2010 
Orlando, FL 
 
PROFESSIONAL AFFILIATIONS 
 
 Sigma Xi Society, Student Member          
2012-2013 
 
 
 Indiana Physiology Society, Student Member      
2010-2013 
 American Physiological Society, Student Member                  
2009-2013 
 Golden Key Honors Society  
2008-2013 
 
PRESENTATIONS     
         
 Research Poster Presentation 
February 2013 
3rd Annual Indiana Physiological Society Meeting 
 Oral Presentation 
October 2012 
Indiana University Center for Diabetes Research Seminar Series 
 Research Poster Presentation  
April 2012 
2012 IUPUI Research Day 
 Research Poster Presentation  
February 2012  
Keystone Symposium: Pathogenesis of Diabetes 
 Research Poster Presentation 
February 2012 
2nd Annual Indiana Physiological Society Meeting 
 Oral Presentation 
January 2012 
Metabolism and Islet Biology Seminar Series  
 Thesis Proposal Oral Presentation  
September 2011 
Department of Cellular & Integrative Physiology Seminar Series 
 Oral Presentation  
August 2011 
2011 Sigma Xi Biomedical Research Competition 
 Research Poster Presentation  
April 2011 
2011 IUPUI Research Day 
 Research Poster Presentation 
February 2011 
Indiana Biomedical Gateway Program Recruitment Poster Session 
 Research Poster Presentation 
February 2011 
1st Annual Indiana Physiological Society Meeting 
 Oral Presentation 
January 2011 
IUPUI Center for Membrane Biosciences Meeting 
 
 
 
 
 Oral Presentation 
August 2010 
Department of Cellular & Integrative Physiology Seminar Series 
 Research Poster Presentation 
June 2010 
70th Scientific Sessions of the American Diabetes Association 
 Oral Presentation  
May 2010 
Sigma Xi Biomedical Research Competition 
 Research Poster Presentation 
October 2009 
2009 Indiana Physiology Statewide Departmental Retreat 
 
AWARDS   
           
 National Institute of Diabetes 
2012 
Travel Award for Keystone Symposia        
 Graduate and Professional Student Government      
2011 
Educational Enhancement Grant        
 1st Place Presentation: 2011 Sigma Xi Biomedical Research Competition 
2011 
 3rd Place Presentation: 2010 Sigma Xi Biomedical Research Competition 
2010 
 Indiana University Travel Fellowship         
2008 
 Induction into Golden Key Honor Society        
2008 
 Induction into Phi Lambda Upsilon Chemistry Honor Society                         
2007 
 Mini Marathon Finisher                                                                      
2007 
 Valparaiso University Deans Award          
2003-2007 
 
RESEARCH INTERESTS 
 
 Cellular and molecular mechanisms of insulin resistance 
 Regulation of glucose and lipid metabolism  
 Mechanisms of lipoprotein metabolism  
 
 
 
 
 
 
RESEARCH EXPERTISE 
 
 Cell culture and treatments (L6 myotubes and 3T3-L1 adipocytes) 
 Preparation and analysis of protein: SDS-PAGE 
 Western blot analyses 
 Whole cell immunofluorescence 
 Plasma membrane sheet assays 
 Subcellular fractionation 
 Fluorescent and confocal microscopy in cultured cells and intact tissue 
 Animal care and maintenance (mice) 
 Dissection: rodent brain, heart, liver, kidney, pancreas, hindlimb and 
soleus muscle, epididymal fat pads 
 Intraperitoneal glucose tolerance testing (mice) 
 Intraperitoneal insulin tolerance testing (mice) 
 Blood collection (mice and rats) 
 Enzyme-linked immunosorbent assays 
 2-deoxyglucose uptake assays (skeletal muscle tissue and cultured cells) 
 Amplex red cholesterol assay 
 Immunoprecipitation 
 Chromatin immunoprecipitation 
 Primer design 
 Electroporation and plasmid transfection 
 Luciferase assays 
 siRNA knockdown 
 Preparation and analysis of DNA and RNA: PCR, sequencing, agarose 
and non-denaturing polyacrylamide gel electrophoresis, plasmid isolation, 
restriction digest, ligation, vector construction, isolation and purification of 
DNA and RNA   
 
TRAINING EXPERIENCES   
         
Indiana University School of Medicine     
May 2009-May 2013 
Department of Cellular and Integrative Physiology 
Mentor: Jeffrey S. Elmendorf, Ph.D.  
 
Indiana University School of Medicine    
January 2009-May 2009 
Department of Cellular & Integrative Physiology  
Mentor: David P. Basile, Ph.D.       
 
Indiana University School of Medicine                   
August 2008-January 2009  
Department of Neuroscience  
Mentor: Dena Davidson, Ph.D.  
 
 
 
Valparaiso University 
August 2006-May 2007  
Developmental Biology Department 
Mentor: Grayson Davis, Ph.D.  
 
Purdue University            
May 2006-August 2006 
Birck Nanotechnology Center, Electrical and Computer Engineering Department 
Mentor: David Janes, Ph.D.  
 
TEACHING EXPERIENCE 
 
Indiana University School of Medicine                
G715 Biochemical Basis of Biological Processes  
August 2010-May 2011 
Teaching Assistant  
 
Valparaiso University: Department of Biology                            
BIO-171 and BIO-172 Unity and Diversity of Life 
August 2005-May 2007 
Laboratory Assistant 
 
Valparaiso University: Department of Physics 
PHYS-141 and PHYS-142 Mechanics and Heat, Electricity Magnetism & Waves 
August 2006-May 2007 
Teaching Assistant 
 
PROFESSIONAL AND UNIVERSITY SERVICE 
        
 Indiana University School of Medicine Student Mentor 
2012-2013 
 Graduate and Professional Student Government        
2011-2013 
President, School of Medicine  
 Indiana Physiological Society              
2010-2013 
Student Councilor   
 Indiana University School of Medicine Graduate Committee                 
2009-2013 
Student Representative 
 Indiana University School of Medicine Student Ambassador 
2009-2013 
Student Coordinator for Campus Visits 
 Indiana University School of Medicine Campus Visit Student Panel  
2012 
Member and Mock Interviewee 
 
 
 Indiana University School of Medicine Getting You into IUPUI  
2012 
Student Panel Member 
 Department of Cellular & Integrative Physiology Retreat 
2011 
Moderator and Organizer for Graduate Student Session 
 Valparaiso University: Residential Life             
2005-2006 
Resident Assistant 
  
COMMUNITY SERVICE 
 
 Valparaiso University  
2006-2007 
Judicial Board Coordinator 
 Valparaiso University   
2006-2007 
Biology Club Vice President       
 Valparaiso University   
2006-2007 
Habitat for Humanity Build Coordinator                   
 Valparaiso University Café Manna           
2005-2007 
Student Volunteer, Prepared & Served Meals to Underprivileged Families 
 Campus Crusade for Christ                      
2004-2007 
Leadership Team, Outreach Coordinator               
 
 
 
